<SEC-DOCUMENT>0001193125-21-096768.txt : 20210326
<SEC-HEADER>0001193125-21-096768.hdr.sgml : 20210326
<ACCEPTANCE-DATETIME>20210326172100
ACCESSION NUMBER:		0001193125-21-096768
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20210315
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210326
DATE AS OF CHANGE:		20210326

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tilray, Inc.
		CENTRAL INDEX KEY:			0001731348
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38594
		FILM NUMBER:		21778568

	BUSINESS ADDRESS:	
		STREET 1:		1100 MAUGHAN ROAD
		CITY:			NANAIMO
		STATE:			A1
		ZIP:			V9X 1J2
		BUSINESS PHONE:		2064329325

	MAIL ADDRESS:	
		STREET 1:		1100 MAUGHAN ROAD
		CITY:			NANAIMO
		STATE:			A1
		ZIP:			V9X 1J2
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d117514d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:tlry="http://www.tilray.com/20210315" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:srt-types="http://fasb.org/srt/2020-01-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body>
 <div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_AmendmentFlag_duration_2021-03-15_to_2021-03-15" name="dei:AmendmentFlag" contextRef="duration_2021-03-15_to_2021-03-15">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey_duration_2021-03-15_to_2021-03-15" name="dei:EntityCentralIndexKey" contextRef="duration_2021-03-15_to_2021-03-15">0001731348</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="tlry-20210315.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2021-03-15_to_2021-03-15"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001731348</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-03-15</xbrli:startDate> <xbrli:endDate>2021-03-15</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2021-03-15_to_2021-03-15">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2021-03-15_to_2021-03-15" format="ixt:datemonthdayyearen">March&#160;15, 2021</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric contextRef="duration_2021-03-15_to_2021-03-15" name="dei:EntityRegistrantName">Tilray, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2021-03-15_to_2021-03-15" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric contextRef="duration_2021-03-15_to_2021-03-15" name="dei:EntityFileNumber">001-38594</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric contextRef="duration_2021-03-15_to_2021-03-15" name="dei:EntityTaxIdentificationNumber">82-4310622</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr> </table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric contextRef="duration_2021-03-15_to_2021-03-15" name="dei:EntityAddressAddressLine1">1100 Maughan Rd</ix:nonNumeric>.,</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric contextRef="duration_2021-03-15_to_2021-03-15" name="dei:EntityAddressCityOrTown">Nanaimo</ix:nonNumeric>, <ix:nonNumeric contextRef="duration_2021-03-15_to_2021-03-15" name="dei:EntityAddressStateOrProvince">BC</ix:nonNumeric>, <ix:nonNumeric contextRef="duration_2021-03-15_to_2021-03-15" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen">Canada</ix:nonNumeric></p></td>
<td style="vertical-align:bottom"> </td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2021-03-15_to_2021-03-15" name="dei:EntityAddressPostalZipCode">V9X 1J2</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr> </table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: (<ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2021-03-15_to_2021-03-15">844</ix:nonNumeric>) <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2021-03-15_to_2021-03-15">845-7291</ix:nonNumeric></span></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2021-03-15_to_2021-03-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2021-03-15_to_2021-03-15" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2021-03-15_to_2021-03-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr> </table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric contextRef="duration_2021-03-15_to_2021-03-15" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"><p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr> </table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title&#160;of&#160;each&#160;class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name&#160;of&#160;each&#160;exchange</p><p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on&#160;which&#160;registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2021-03-15_to_2021-03-15">Class&#160;2&#160;Common&#160;Stock,&#160;$0.0001&#160;par&#160;value&#160;per&#160;share</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2021-03-15_to_2021-03-15" name="dei:TradingSymbol">TLRY</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric contextRef="duration_2021-03-15_to_2021-03-15" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr> </table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;&#160;240.12b-2</span> of this chapter).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2021-03-15_to_2021-03-15" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div> <p style='page-break-before:always'></p> <hr style="color:#999999;height:3px;width:100%" /> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top"><span style="font-weight:bold">Item&#160;8.01.</span></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events.</p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously disclosed on December&#160;15, 2020, Tilray, Inc., a Delaware corporation (&#8220;Tilray&#8221;), and Aphria Inc., a corporation existing under the laws of the Province of Ontario (&#8220;Aphria&#8221;), entered into an Arrangement Agreement, as amended on February 19, 2021, (the &#8220;Arrangement Agreement&#8221;), pursuant to which all of the issued and outstanding common shares of Aphria will be exchanged for Class&#160;2 common stock of Tilray, in accordance with a specified exchange ratio, pursuant to a plan of arrangement under the Business Corporations Act (Ontario) (the &#8220;Arrangement&#8221;). On March&#160;12, 2020, Tilray filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) a definitive joint proxy statement/circular (the &#8220;Proxy Statement/Circular&#8221;) with respect to the special meeting of Tilray stockholders scheduled to be held on April&#160;16, 2021 pursuant to the Arrangement.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Litigation Related to the Merger </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Arrangement, after the Proxy Statement/Circular was filed, three stockholder lawsuits have been filed:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top">(i)</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">in the United States District Court for the Southern District of New York, captioned<span style="font-style:italic">&#160;Violini v. Tilray, Inc. et al.</span>, Case No. <span style="white-space:nowrap"><span style="white-space:nowrap">1:21-cv-02256</span></span> (the &#8220;Violini Complaint&#8221;);</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top">(ii)</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">in the United States District Court for the Southern District of New York, captioned<span style="font-style:italic"></span><span style="font-style:italic">&#160;Barron-Archer v. Tilray, Inc. et al.</span>, Case <span style="white-space:nowrap"><span style="white-space:nowrap">No.&#160;1:21-cv-02497</span></span> (the &#8220;Barron-Archer Complaint&#8221;); and</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top">(ii)</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">in the United States District Court for the Eastern District of New York, captioned<span style="font-style:italic"></span><span style="font-style:italic">&#160;Reveles v. Tilray, Inc. et al.</span>, Case <span style="white-space:nowrap"><span style="white-space:nowrap">No.&#160;1:21-cv-01543</span></span> (the &#8220;Reveles Complaint&#8221;), and together with the Violini Complaint and the Barron-Archer Complaint, the &#8220;Complaints&#8221;)</p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Complaints generally allege, among other things, that Tilray and the members of its Board of Directors omitted purportedly material information from the Proxy Statement/Circular. The Barron-Archer Complaint includes the additional claim that the members of the Board of Directors breached their fiduciary duties with respect to the alleged omissions.&#160;The Complaints seek, among other things, additional disclosure of facts relating to the Arrangement and/or injunctive relief. Additional similar lawsuits may be filed in the future. Tilray believes that the plaintiffs&#8217; allegations in the Complaints lack merit. If additional similar complaints are filed, or if the Complaints are amended, absent new or different allegations that are material, Tilray will not necessarily disclose such additional filings or subsequent amendments. The foregoing description is qualified in its entirety by reference to the Complaints which are attached hereto as Exhibits 99.1, 99.2, and 99.3 are incorporated by reference herein.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Additional Information and Where to Find It</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the proposed business combination (the &#8220;Transaction&#8221;), Tilray has filed a Proxy Statement/Circular containing important information about the Transaction and related matters.&#160;The Proxy Statement/Circular has also been made available by Aphria and Tilray on their respective SEDAR profiles. Additionally, Aphria and Tilray will file other relevant materials in connection with the Transaction with the applicable securities regulatory authorities. Investors and security holders of Aphria and Tilray are urged to carefully read the entire Proxy Statement/Circular (including any amendments or supplements to such documents), respectively,&#160;before making any voting decision with respect to the Transaction because they contain important information about the Transaction and the parties to the Transaction. The Proxy Statement/Circular will be mailed to the Aphria Shareholders and Tilray Stockholders and is accessible on the SEDAR and EDGAR profiles of the respective companies.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors and security holders of Tilray can obtain a free copy of the Proxy Statement/Circular, as well as other relevant filings containing information about Tilray and the Transaction, including materials incorporated by reference into the Proxy Statement/Circular, without charge, at the SEC&#8217;s website (<span style="text-decoration:underline">www.sec.gov</span>) or from Tilray by contacting Tilray&#8217;s Investor Relations <span style="white-space:nowrap">at&#160;(203)&#160;682-8253,&#160;by&#160;email</span> at<span style="text-decoration:underline">&#160;Raphael.Gross@icrinc.com</span>, or by going to Tilray&#8217;s Investor Relations page on its website at <span style="text-decoration:underline">https://ir.tilray.com/investor-relations</span>&#160;and clicking on the link titled &#8220;Financials.&#8221;</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors and security holders of Aphria are able to obtain a free copy of the Proxy Statement/Circular, as well as other relevant filings containing information about Aphria and the Transaction, including materials incorporated by reference into the Proxy Statement/Circular, without charge, under Aphria&#8217;s profile on SEDAR at<span style="text-decoration:underline">&#160;www.sedar.com</span>&#160;or from Aphria by contacting Aphria&#8217;s investor relations at<span style="text-decoration:underline">&#160;investors@aphria.com</span>.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Participants in the Solicitation</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tilray and Aphria and certain of their respective directors, executive officers and employees may be deemed to be participants in the solicitation of Tilray proxies in respect of the Transaction. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to Tilray stockholders in connection with the Transaction will be set forth in the Tilray proxy</p></div></div> <p style='page-break-before:always'></p> <hr style="color:#999999;height:3px;width:100%" /> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> statement for the Transaction when available. Other information regarding the participants in the Tilray proxy solicitation and a description of their direct and indirect interests in the Transaction, by security holdings or otherwise, will be contained in such proxy statement and other relevant materials to be filed with the SEC in connection with the Transaction. Copies of these documents may be obtained, free of charge, from the SEC or Tilray as described in the preceding paragraph.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Notice Regarding Forward-Looking Statements</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain information in this email constitutes forward-looking information or forward-looking statements (together, &#8220;forward-looking statements&#8221;) under Canadian securities laws and within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor created by such sections and other applicable laws. The forward-looking statements are expressly qualified by this cautionary statement. Forward-looking statements are provided for the purpose of presenting information about management&#8217;s current expectations and plans relating to the future, and readers are cautioned that such statements may not be appropriate for other purposes. Any information or statements that are contained in this email that are not statements of historical fact may be deemed to be forward-looking statements, including, but not limited to, statements in this email with regards to: (i)&#160;statements relating to the strategic business combination of Aphria and Tilray and the expected timing and closing of the Transaction; Transaction including, receipt of required shareholder approvals, court approvals and satisfaction of other closing customary conditions; (ii)&#160;estimates <span style="white-space:nowrap">of&#160;pro-forma&#160;financial</span> information of the Combined Company, including in respect of expected revenues and production of cannabis; (iii)&#160;the expected strategic and financial benefits of the business combination, including estimates of future cost reductions, synergies, <span style="white-space:nowrap">including&#160;expected&#160;pre-tax&#160;synergies,&#160;savings</span> and efficiencies; (iv)&#160;statements that the Combined Company anticipates having scalable <span style="white-space:nowrap">medical&#160;and&#160;adult-use&#160;cannabis&#160;platforms</span> expected to strengthen the leadership position in Canada, internationally and, eventually in the United States; (v)&#160;statements that the Combined Company is expected to offer a diversified and branded product offering and <span style="white-space:nowrap"><span style="white-space:nowrap"><span style="white-space:nowrap">distribution&#160;footprint,&#160;state-of-the-art&#160;cultivation,&#160;processing</span></span></span> and manufacturing facilities; (vi)&#160;statements in respect of operational efficiencies expected to be generated as a result of the Transaction in the amount of approximately <span style="white-space:nowrap">C$100&#160;million&#160;of&#160;pre-tax&#160;annual&#160;cost</span> synergies; (vii)&#160;statements regarding the value and returns to shareholders expected to be generated by the business combination; (viii)&#160;expectations of future balance sheet strength and future equity; (ix)&#160;expectations regarding the Combined Company&#8217;s future M&amp;A strategy; and (x)&#160;the expectation that the Combined Company&#8217;s shares will be listed on the Toronto Stock Exchange concurrently with, or as soon as possible after, the closing of the Transaction. Aphria and Tilray use words such as &#8220;forecast&#8221;, &#8220;future&#8221;, &#8220;should&#8221;, &#8220;could&#8221;, &#8220;enable&#8221;, &#8220;potential&#8221;, &#8220;contemplate&#8221;, &#8220;believe&#8221;, &#8220;anticipate&#8221;, &#8220;estimate&#8221;, &#8220;plan&#8221;, &#8220;expect&#8221;, &#8220;intend&#8221;, &#8220;may&#8221;, &#8220;project&#8221;, &#8220;will&#8221;, &#8220;would&#8221; and the negative of these terms or similar expressions to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Certain material factors or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this email, including the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary shareholder and court approvals for the Transaction, the ability of the parties to satisfy, in a timely manner, the conditions to closing of the Transaction and other expectations and assumptions concerning the Transaction. Forward-looking statements reflect current beliefs of management of Aphria and Tilray with respect to future events and are based on information currently available to each respective management team including the reasonable assumptions, estimates, analysis and opinions of management of Aphria and Tilray considering their experience, perception of trends, current conditions and expected developments as well as other factors that each respective management believes to be relevant as at the date such statements are made. Forward-looking statements involve significant known and unknown risks and uncertainties. Many factors could cause actual results, performance or achievement to be materially different from any future forward-looking statements. Factors that may cause such differences include, but are not limited to, risks assumptions and expectations described in Aphria&#8217;s and Tilray&#8217;s critical accounting policies and estimates; the adoption and impact of certain accounting pronouncements; Aphria&#8217;s and Tilray&#8217;s future financial and operating performance; the competitive and business strategies of Aphria and Tilray; the intention to grow the business, operations and potential activities of Aphria and Tilray; the ability of Aphria and Tilray to complete the Transaction; Aphria&#8217;s and Tilray&#8217;s ability to provide a return on investment; Aphria&#8217;s and Tilray&#8217;s ability to maintain a strong financial position and manage costs, the ability of Aphria and Tilray to maximize the utilization of their existing assets and investments and that the completion of the Transaction is subject to the satisfaction or waiver of a number of conditions as set forth in the Arrangement Agreement. There can be no assurance as to when these conditions will be satisfied or waived, if at all, or that other events will not intervene to delay or result in the failure to complete the Transaction. There is a risk that some or all the expected benefits of the Transaction may fail to materialize or may not occur within the time periods anticipated by Aphria and Tilray. The challenge of coordinating previously independent businesses makes evaluating the business and future financial prospects of the Combined Company following the Transaction difficult. Material risks that could cause actual results to differ from forward-looking statements also include the inherent uncertainty associated with the financial and other projections a well as market changes arising from governmental actions or market conditions in response <span style="white-space:nowrap">to&#160;the&#160;COVID-19&#160;public&#160;health</span> crisis; the prompt and effective integration of the Combined Company; the ability to achieve the anticipated synergies and value-creation contemplated by the Transaction; the risk associated with Aphria&#8217;s and Tilray&#8217;s ability to obtain the approval of the proposed transaction by their shareholders required to consummate the Transaction and the timing of the closing of the Transaction, including the risk that the conditions to the Transaction are not satisfied on a timely basis or at all; the risk that a consent or authorization that may be required for the Transaction is not obtained or is obtained subject to conditions that are not anticipated; the outcome of any legal proceedings that may be instituted against the parties and others related to the Arrangement Agreement; unanticipated difficulties or expenditures relating to the Transaction, the response of business partners and retention as a</p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p></div></div> <p style='page-break-before:always'></p> <hr style="color:#999999;height:3px;width:100%" /> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> result of the announcement and pendency of the Transaction; risks relating to the value of Tilray&#8217;s common stock to be issued in connection with the transaction; the impact of competitive responses to the announcement of the Transaction; and the diversion of management time on transaction-related issues. Readers are cautioned that the foregoing list of factors is not exhaustive. Other risks and uncertainties not presently known to Aphria and Tilray or that Aphria and Tilray presently believe are not material could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of risks and other factors, see the most recently filed annual information form of Aphria and the annual report filed <span style="white-space:nowrap">on&#160;form&#160;10-K&#160;of&#160;Tilray</span> made with applicable securities regulatory authorities and available on SEDAR and EDGAR. The forward-looking statements included in this email are made as of the date of this email and neither Aphria nor Tilray undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.</p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top"><span style="font-weight:bold">Item&#160;9.01.</span></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits</p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits.</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td style="width:92%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; font-size:8pt; font-family:Times New Roman;font-weight:bold">Exhibit&#160;Description</p></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d117514dex991.htm">Complaint, <span style="font-style:italic">Violini v. Tilray, Inc. et al.</span>, Case No. <span style="white-space:nowrap"><span style="white-space:nowrap">1:21-cv-02256,</span></span> filed on March&#160;15, 2021 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d117514dex992.htm">Complaint, <span style="font-style:italic">Barron-Archer v. Tilray, Inc. et al.</span>, Case <span style="white-space:nowrap"><span style="white-space:nowrap">No.&#160;1:21-cv-02497,&#160;filed</span></span> on March&#160;23, 2021 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d117514dex993.htm">Complaint, <span style="font-style:italic">Reveles v. Tilray, Inc. et al.</span>, Case <span style="white-space:nowrap"><span style="white-space:nowrap">No.&#160;1:21-cv-01543,&#160;filed</span></span> on March&#160;24, 2021 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr></table></div></div> <p style='page-break-before:always'></p> <hr style="color:#999999;height:3px;width:100%" /> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0">
<tr>
<td style="width:45%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">TILRAY,&#160;INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: March&#160;26, 2021</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">/s/ Brendan Kennedy</span></p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Brendan Kennedy</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">President and Chief Executive Officer</td></tr></table></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d117514dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES DISTRICT COURT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SOUTHERN DISTRICT OF NEW YORK </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="68%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">PATRICIA VIOLINI,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Case No.:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">Plaintiff, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:6.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">v.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">JURY TRIAL DEMANDED</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">TILRAY,&nbsp;INC.,&nbsp;BRENDAN&nbsp;KENNEDY, CHRISTINE ST.CLARE, REBEKAH DOPP,&nbsp;MICHAEL&nbsp;AUERBACH,&nbsp;and SOREN SCHRODER,</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><U>COMPLAINT FOR VIOLATIONS OF</U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><U>FEDERAL SECURITIES LAWS</U></B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">Defendants.&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Plaintiff, by her undersigned attorneys, for this complaint against defendants, alleges upon
personal knowledge with respect to herself, and upon information and belief based upon, <I>inter alia</I>, the investigation of counsel as to all other allegations herein, as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>BACKGROUND </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1. This action concerns a proposed transaction (&#147;Proposed Transaction&#148;) announced on December&nbsp;16, 2020,
pursuant to which Tilray, Inc. (&#147;Tilray&#148; or the &#147;Company&#148;) will merge with Aphria Inc. (&#147;Aphria&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2. On December&nbsp;15, 2020, Tilray&#146;s Board of Directors (the &#147;Board&#148; or &#147;Individual Defendants&#148;)
caused the Company to enter into an arrangement agreement (the &#147;Merger Agreement&#148;). Pursuant to the terms of the Merger Agreement, each share of Aphria common stock will be converted into approximately 0.8381 shares of Tilray common stock
(the &#147;Merger Consideration&#148;). Upon closing of the Proposed Transaction, stockholders of Aphria will own approximately 62% of the outstanding common stock of Tilray, while stockholders of Tilray are expected to own approximately 38% of
Tilray. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3. On March&nbsp;12, 2021, in order to convince Tilray&#146;s shareholders
to vote in favor of the Proposed Transaction, Defendants filed a materially incomplete and misleading preliminary proxy statement (the &#147;Proxy Statement&#148;) with the United States Securities and Exchange Commission (&#147;SEC&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4. The Proxy Statement omits material information with respect to the Proposed Transaction, which renders the Proxy Statement
false and misleading. Accordingly, Plaintiff alleges herein that defendants violated Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 (the &#147;1934 Act&#148;) in connection with Proxy Statement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5. In addition, a special meeting of Tilray stockholders will be held on April&nbsp;16, 2021 to vote on the Proposed
Transaction (the &#147;Stockholder Vote&#148;). It is therefore imperative that the material information that has been omitted from the Proxy Statement is disclosed prior to the Stockholder Vote so Tilray stockholders can properly exercise their
corporate voting rights and make an informed decision on whether to vote in favor of the merger. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>JURISDICTION&nbsp;&amp; VENUE
</U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6. This Court has jurisdiction over the claims asserted herein pursuant to Section&nbsp;27 of the 1934 Act and 28
U.S.C. &#167;1331 because the claims asserted herein arise under Sections 14(a) and 20(a) of the 1934 Act and Rule <FONT STYLE="white-space:nowrap">14a-9.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7. This Court has jurisdiction over Defendants because each defendant is either a corporation that conducts business in this
District, or is an individual with sufficient minimum contacts with this District so as to make the exercise of jurisdiction by this Court permissible under traditional notions of fair play and substantial justice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8. Venue is proper in this District under Section&nbsp;27 of the Exchange Act, 15 U.S.C. &#167; 78aa, as well as under 28
U.S.C. &#167; 1391, because, among other things: (a)&nbsp;the conduct at issue </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">will have an effect in this District; (b)&nbsp;a substantial portion of the transactions and
wrongs complained of herein, occurred in this District; and (c)&nbsp;certain Defendants have received substantial compensation in this District by doing business here and engaging in numerous activities that had an effect in this District.
Additionally, the Company&#146;s common stock trades on the NASDAQ, which is headquartered in this District. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>THE PARTIES
</U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">9. Plaintiff is, and has been continuously throughout all times relevant hereto, a Tilray shareholder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10. Defendant Tilray is a Delaware corporation and a party to the Merger Agreement. Tilray shares are traded on the NASDAQ
under the ticker symbol &#147;TLRY.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11. Defendant Brendan Kennedy is President, Chief Executive Officer, and a
director of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12. Defendant Christine St. Clare is a director of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">13. Defendant Rebekah Dopp is a director of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">14. Defendant Michael Auerbach is a director of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">15. Defendant Soren Schroder is a director of the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>FACTS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">16. Tilray supplies high-quality medical cannabis products to tens of thousands of patients in fifteen countries spanning five
continents across the world through Tilray&#146;s Subsidiaries in Australia, Canada, Germany, Latin America and Portugal and through agreements with established pharmaceutical distributors. Tilray cultivates medical and <FONT
STYLE="white-space:nowrap">adult-use</FONT> cannabis in Canada and medical cannabis in Europe. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">17. Aphria is a leading global cannabis-lifestyle consumer packaged goods
company, with operations in Canada, the United States, Europe and Latin America. Aphria cultivates, processes, markets and sells medical and <FONT STYLE="white-space:nowrap">adult-use</FONT> cannabis, cannabis-derived extracts and derivative
cannabis products in Canada under the provisions of the Cannabis Act and globally pursuant to applicable international regulations. Aphria, through its SweetWater subsidiary, also manufactures, markets and sells alcoholic beverages in the United
States. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">18. On December&nbsp;15, 2020, Tilray&#146;s Board caused the Company to enter into the Merger Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">19. The Merger Agreement provides that Tilray will merge with and into Aphria with Aphria surviving as a wholly owned
subsidiary of Tilray. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">20. At the Effective Time (as defined in the Merger Agreement), and as a result of the Merger: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">[E]ach Aphria Share outstanding immediately prior to the Effective Time (other than Dissenting Shares held by Aphria Dissenting
Shareholders who are ultimately determined to be entitled to be paid the fair value of their Dissenting Shares as determined in accordance with Article 4), shall be, and shall be deemed to be, transferred by the holder thereof to Tilray (free and
clear of all Liens) in exchange for issuance of the Share Consideration. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">21. The Merger Consideration is unfair because,
among other things, the intrinsic value of the Company is in excess of the amount the Company&#146;s stockholders will receive in connection with the Proposed Transaction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">22. It is therefore imperative that the Company shareholders receive the material information that Defendants have omitted from
the Proxy Statement so that they can meaningfully assess whether the Proposed Transaction is in their best interests prior to the vote. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">23. Section&nbsp;5.1 of the Merger Agreement has a <FONT STYLE="white-space:nowrap">&#147;non-solicitation&#148;</FONT> clause
that prevents </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Tilray from soliciting alternative proposals and constraints its ability to negotiate with
potential buyers: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Section&nbsp;5.1 <U><FONT STYLE="white-space:nowrap">Non-Solicitation</FONT></U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">From the date hereof until the date that this Agreement is terminated pursuant to Article 7, except as expressly provided in
this Article 5, neither Party shall, directly or indirectly, do or authorize or permit any of its Representatives to do, any of the following:(a) solicit, initiate or knowingly encourage or otherwise facilitate (including by way of furnishing or
providing copies of, access to, or disclosure of, any confidential information, properties, facilities, books or records of a Party or any Subsidiary) any Acquisition Proposal in respect of such Party or any inquiries, proposals or offers relating
to any Acquisition Proposal or that could reasonably be expected to lead to an Acquisition Proposal in respect of such Party;(b)enter into, engage in, continue or otherwise participate in any discussions or negotiations with any person (other than
the other Party hereto) regarding any Acquisition Proposal in respect of such Party or any inquiries, proposals or offers relating to any Acquisition Proposal or that could reasonably be expected to constitute or lead to an Acquisition Proposal in
respect of such Party;(c)make a Change in Recommendation;(d)accept, approve, endorse or recommend, execute or enter into, or publicly propose to accept, approve, execute or enter into, any letter of intent, agreement in principle, agreement,
arrangement, offer or understanding in respect of an Acquisition Proposal (other than a confidentiality and standstill agreement contemplated under Section&nbsp;5.3(1)). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">24. In addition, Section&nbsp;7.3 of the Merger Agreement requires Tilray to pay up to a $65,000,000 &#147;termination
fee&#148; in the event this agreement is terminated by Tilray and improperly constrains the Company from obtaining a superior offer. Such a termination fee is excessive and unduly restrictive to Tilray&#146;s ability to consider other offers. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">25. Defendants filed the Proxy Statement with the SEC in connection with the Proposed Transaction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">26. As alleged herein, the Proxy Statement omits material information with respect to the Proposed Transaction, which renders
the Proxy Statement false and misleading. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">27. First, the Proxy Statement omits material information regarding
Tilray&#146;s, Aphria&#146;s, and the pro forma company&#146;s financial projections. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">28. With respect to Tilray&#146;s financial projections, the Proxy Statement
fails to disclose all line items used to calculate net revenue, gross profit, adjusted EBITDA, EBIT, unlevered free cash flow (calculated by Cowen), and unlevered free cash flow (calculated by Imperial). The Proxy Statement also fails to disclose a
reconciliation of all <FONT STYLE="white-space:nowrap">non-GAAP</FONT> to GAAP metrics. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">29. With respect to Aphria&#146;s
financial projections, the Proxy Statement fails to disclose all line items used to calculate net revenue, gross profit, adjusted EBITDA excluding NCI, <FONT STYLE="white-space:nowrap">non-GAAP</FONT> gross profit, EBIT, and unlevered free cash
flow. The Proxy Statement also fails to disclose a reconciliation of all <FONT STYLE="white-space:nowrap">non-GAAP</FONT> to GAAP metrics. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">30. With respect to the pro forma company&#146;s financial projections, the Proxy Statement fails to disclose all line items
used to calculate <FONT STYLE="white-space:nowrap">non-GAAP</FONT> gross profit, adjusted EBITDA, and unlevered free cash flow. The Proxy Statement also fails to disclose a reconciliation of all <FONT STYLE="white-space:nowrap">non-GAAP</FONT> to
GAAP metrics. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">31. The disclosure of projected financial information is material information necessary for stockholders to
gain an understanding of the basis for any projections as to the future financial performance of the combined company. In addition, this information is material and necessary for stockholders to understand the financial analyses performed by the
companies&#146; financial advisors rendered in support of any fairness opinion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">32. Second, the Proxy Statement omits
material information regarding the analyses performed by the Company&#146;s financial advisors Cowen and Company, LLC (&#147;Cowen&#148;) and Imperial Capital, LLC (&#147;Imperial&#148;) and Aphria&#146;s financial advisor Jefferies LLC
(&#147;Jefferies&#148;) in connection with the Proposed Transaction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">33. With respect to Cowen&#146;s <I>Analysis of
Selected Publicly-Traded Companies</I>, the Proxy Statement fails to include the individual metrics for each company observed. This </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">information must be disclosed to make the Proxy Statement not materially misleading to
Tilray stockholders and provide stockholders with full and relevant information in considering how to vote. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">34. With
respect to Cowen&#146;s <I>Tilray Discounted Cash Flow Analysis,</I> the Proxy Statement fails to include: (i)&nbsp;the terminal value of Tilray at December&nbsp;31, 2023, (ii) the individual inputs and assumptions underlying the range of discount
rates of 10.0% to 12.0%, (iii) Tilray&#146;s estimated weighted average cost of capital (&#147;WACC&#148;), and (iv)&nbsp;Cowen&#146;s full basis for applying an adjusted EBITDA multiples range of 15.0x to 20.0x. This information must be disclosed
to make the Proxy Statement not materially misleading to Tilray stockholders and provide stockholders with full and relevant information in considering how to vote. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">35. With respect to Cowen&#146;s <I>Aphria Discounted Cash Flow Analysis Based on Aphria </I><I>Management Projections,</I> the
Proxy Statement fails to include: (i)&nbsp;the terminal value of Aphria at May&nbsp;31, 2024, (ii) the individual inputs and assumptions underlying the range of discount rates of 8.5% to 10.5%, (iii) Aphria&#146;s estimated WACC, and
(iv)&nbsp;Cowen&#146;s full basis for applying an adjusted EBITDA multiples range of 15.0x to 20.0x. This information must be disclosed to make the Proxy Statement not materially misleading to Tilray stockholders and provide stockholders with full
and relevant information in considering how to vote. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">36. With respect to Cowen&#146;s <I>Aphria Discounted Cash Flow
Analysis Based on Aphria Management Projections as Adjusted by Tilray Management,</I> the Proxy Statement fails to include: (i) the terminal value of Aphria at May&nbsp;31, 2024, (ii) the individual inputs and assumptions underlying the range of
discount rates of 8.5% to 10.5%, (iii) Aphria&#146;s estimated WACC, and (iv)&nbsp;Cowen&#146;s full basis for applying an adjusted EBITDA multiples range of 15.0x to 20.0x. This information must be disclosed to make the Proxy Statement not
materially misleading to Tilray </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">stockholders and provide stockholders with full and relevant information in considering how
to vote. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">37. With respect to Imperial&#146;s <I>Comparable Companies Analysis</I>, the Proxy Statement fails to include
the individual metrics for each company observed. This information must be disclosed to make the Proxy Statement not materially misleading to Tilray stockholders and provide stockholders with full and relevant information in considering how to vote.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">38. With respect to Imperial&#146;s <I>Precedent Transactions Analysis</I>, the Proxy Statement fails to include the
individual metrics for each transaction observed. This information must be disclosed to make the Proxy Statement not materially misleading to Tilray stockholders and provide stockholders with full and relevant information in considering how to vote.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">39. With respect to Imperial&#146;s <I>Discounted Cash Flow Analysis</I>, the Proxy Statement fails to include:
(i)&nbsp;estimated terminal values for Tilray and Aphria, (ii)&nbsp;Imperial&#146;s full basis for applying TEV/EBITDA multiples of 20x to 22x for Tilray and 18x to 20x for Aphria and a range of perpetuity growth rates of 8.5% to 9.5% to the free
cash flow, (iii)&nbsp;the individual inputs and assumptions underlying the discount rate of 12.5%, and (iv)&nbsp;WACC for Tilray and Aphria. This information must be disclosed to make the Proxy Statement not materially misleading to Tilray
stockholders and provide stockholders with full and relevant information in considering how to vote. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">40. With respect to
Jefferies&#146; <I>Discounted Cash Flow Analysis of Aphria Stand-Alone, and of Aphria Shareholders&#146; Share of the Combined Company at the Exchange Ratio Analysis</I>, the Proxy Statement fails to include: (i)&nbsp;the individual inputs and
assumptions underlying the range of discount rates of 10.0% to 12.0% and 9.8% to 11.8%, (ii) Aphria&#146;s and the combined company&#146;s estimated WACC, (iii)&nbsp;the range of Aphria&#146;s terminal year values, (iii)&nbsp;Jefferies&#146; full
basis for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">applying exit multiples ranging from 10.5x to 14.5x, and (iv)&nbsp;estimates of the tax
benefits from <FONT STYLE="white-space:nowrap">non-capital</FONT> loss carry forward as provided by Aphria management. This information must be disclosed to make the Proxy Statement not materially misleading to Tilray stockholders and provide
stockholders with full and relevant information in considering how to vote. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">41. With respect to Jefferies&#146;
<I>Discounted Cash Flow Analyses of Tilray Stand-Alone and Tilray Including Synergies</I>, the Proxy Statement fails to include: (i)&nbsp;the individual inputs and assumptions underlying the range of discount rates of 10.0% to 12.0% and 9.8% to
11.8%, (ii) Tilray&#146;s and the combined company&#146;s estimated WACC, (iii)&nbsp;the range of Tilray&#146;s terminal year values, (iii)&nbsp;Jefferies&#146; full basis for applying exit multiples ranging from 10.5x to 14.5x, and
(iv)&nbsp;estimates of the tax benefits from <FONT STYLE="white-space:nowrap">non-capital</FONT> loss carry forward as provided by Tilray management. This information must be disclosed to make the Proxy Statement not materially misleading to Tilray
stockholders and provide stockholders with full and relevant information in considering how to vote. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">42. With respect to
Jefferies&#146; <I>Selected Public Companies Analysis</I>, the Proxy Statement fails to include the individual metrics for each company observed. This information must be disclosed to make the Proxy Statement not materially misleading to Tilray
stockholders and provide stockholders with full and relevant information in considering how to vote. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">43. The omission of
the above-referenced material information renders the Proxy false and misleading. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">44. The above-referenced omitted
information, if disclosed, would significantly alter the total mix of information available to the Company&#146;s stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CLAIMS FOR RELIEF </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COUNT I </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>(AGAINST
ALL DEFENDANTS FOR VIOLATIONS OF SECTION 14(a) OF THE </U></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXCHANGE ACT AND RULE <FONT STYLE="white-space:nowrap">14a-9</FONT>
PROMULGATED THEREUNDER) </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">45. Plaintiff incorporates each and every allegation set forth above as if fully set
forth herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">46. Rule <FONT STYLE="white-space:nowrap">14a-9,</FONT> promulgated by the SEC pursuant to
Section&nbsp;14(a) of the Exchange Act, requires that proxy communications with stockholders shall not contain &#147;any statement which, at the time and in the light of the circumstances under which it is made, is false or misleading with respect
to any material fact, or which omits to state any material fact necessary in order to make the statements therein not false or misleading.&#148; 17 C.F.R. &#167; <FONT STYLE="white-space:nowrap">240.14a-9.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">47. Defendants issued the Proxy with the intention of soliciting stockholder support for the Proposed Transaction. Each of the
Defendants reviewed and authorized the dissemination of the Proxy and the use of their name in the Proxy, which fails to provide critical information regarding, among other things, the financial projections that were prepared by the Company and
relied upon by the Board in recommending the Company&#146;s stockholders vote in favor of the Proposed Transaction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">48. In
so doing, Defendants made untrue statements of fact and/or omitted material facts necessary to make the statements made not misleading. By virtue of their roles as officers and/or directors, each of the Individual Defendants were aware of the
omitted information but failed to disclose such information, in violation of Section&nbsp;14(a). The Individual Defendants were therefore negligent, as they had reasonable grounds to believe material facts existed that were misstated or omitted from
the Proxy, but nonetheless failed to obtain and disclose such information to stockholders as required. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">49. The preparation of a Proxy by corporate insiders containing materially
false or misleading statements or omitting a material fact constitutes negligence. Defendants were negligent in preparing and reviewing the Proxy. Defendants were also negligent in choosing to omit material information from the Proxy or failing to
notice the material omissions in the Proxy upon reviewing it, which they were required to do carefully. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">50. The
misrepresentations and omissions in the Proxy are material to Plaintiff, who will be deprived of her right to cast an informed vote if such misrepresentations and omissions are not corrected prior to the vote on the Proposed Transaction. Plaintiff
has no adequate remedy at law. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COUNT II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>(AGAINST THE INDIVIDUAL DEFENDANTS FOR VIOLATIONS OF </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SECTION 20(a) OF THE EXCHANGE ACT) </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">51. Plaintiff incorporates each and every allegation set forth above as if fully set forth herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">52. The Individual Defendants acted as controlling persons of the Company within the meaning of Section&nbsp;20(a) of the
Exchange Act as alleged herein. By virtue of their positions as directors of the Company, and participation in and/or awareness of the Company&#146;s operations and/or intimate knowledge of the incomplete and misleading statements contained in the
Proxy filed with the SEC, they had the power to influence and control and did influence and control, directly or indirectly, the decision making of the Company, including the content and dissemination of the various statements that Plaintiff
contends are materially incomplete and misleading. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">53. Each of the Individual Defendants was provided with or had
unlimited access to copies of the Proxy and other statements alleged by Plaintiff to be misleading prior to and/or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">shortly after these statements were issued and had the ability to prevent the issuance of
the statements or cause the statements to be corrected. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">54. In particular, each of the Individual Defendants had direct
and supervisory involvement in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations of the Company, and, therefore, is presumed to have had the power to control or influence the particular
transactions giving rise to the Exchange Act violations alleged herein, and exercised the same. The omitted information identified above was reviewed by the Board prior to voting on the Proposed Transaction. The Proxy at issue contains the unanimous
recommendation of the Board to approve the Proposed Transaction. The Individual Defendants were thus directly involved in the making of the Proxy. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">55. In addition, as the Proxy sets forth at length, and as described herein, the Individual Defendants were involved in
negotiating, reviewing, and approving the Merger Agreement. The Proxy purports to describe the various issues and information that the Individual Defendants reviewed and considered. The Individual Defendants participated in drafting and/or gave
their input on the content of those descriptions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">56. By virtue of the foregoing, the Individual Defendants have violated
Section&nbsp;20(a) of the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">57. As set forth above, the Individual Defendants had the ability to exercise
control over and did control a person or persons who have each violated Section&nbsp;14(a) and Rule <FONT STYLE="white-space:nowrap">14a-9,</FONT> by their acts and omissions as alleged herein. By virtue of their positions as controlling persons,
these defendants are liable pursuant to Section&nbsp;20(a) of the Exchange Act. As a direct and proximate result of Individual Defendants&#146; conduct, Plaintiff will be irreparably harmed. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">58. Plaintiff has no adequate remedy at law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>PRAYER FOR RELIEF </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREFORE</B>, Plaintiff prays for judgment and relief as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A. Preliminarily and permanently enjoining defendants and all persons acting in concert with them from proceeding with,
consummating, or closing the Proposed Transaction; B. In the event defendants consummate the Proposed Transaction, rescinding it and setting it aside or awarding rescissory damages; C. Directing the Individual Defendants to disseminate a proxy that
does not contain any untrue statements of material fact and that states all material facts required in it or necessary to make the statements contained therein not misleading; D. Declaring that defendants violated Sections 14(a) and/or 20(a) of the
1934 Act, as well as Rule <FONT STYLE="white-space:nowrap">14a-9</FONT> promulgated thereunder; E. Awarding Plaintiff the costs of this action, including reasonable allowance for Plaintiff&#146;s attorneys&#146; and experts&#146; fees; and F.
Granting such other and further relief as this Court may deem just and proper. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>JURY DEMAND </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Plaintiff hereby requests a trial by jury on all issues so triable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: March&nbsp;15, 2021<B>&nbsp;&nbsp;&nbsp;&nbsp;</B><B> </B> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>MOORE KUEHN, PLLC</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>/s/Justin Kuehn</I></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Justin A. Kuehn</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Fletcher W. Moore</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">30 Wall Street,
8<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> floor</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">New York, New York 10005</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Tel: (212) <FONT STYLE="white-space:nowrap">709-8245</FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>jkuehn@moorekuehn.com</U></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>fmoore@moorekuehn.com</U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Attorneys for Plaintiff</I></P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d117514dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES DISTRICT COURT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE SOUTHERN DISTRICT OF NEW YORK </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="69%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ALICIA BARRON-ARCHER,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Case No.
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">Plaintiff, &nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:6.00em; font-size:10pt; font-family:Times New Roman" ALIGN="justify">v.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">JURY TRIAL DEMANDED</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TILRAY,&nbsp;INC.,&nbsp;BRENDAN&nbsp;KENNEDY,
CHRISTINE&nbsp;ST.CLARE,&nbsp;REBEKAH</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DOPP,&nbsp;MICHAEL&nbsp;AUERBACH,&nbsp;and</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">SOREN SCHRODER,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="right" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">Defendants.&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>COMPLAINT FOR VIOLATION OF THE SECURITIES EXCHANGE ACT OF 1934 </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Plaintiff, Alicia Barron-Archer (&#147;Plaintiff&#148;), by her undersigned attorneys, for this Complaint against defendants,
alleges upon personal knowledge with respect to herself, and upon information and belief based upon, <I>inter alia</I>, the investigation of counsel, as to all other allegations herein, as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>NATURE OF THE ACTION </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1. This is an action brought by Plaintiff against Tilray, Inc. (&#147;Tilray&#148; or the &#147;Company&#148;) and the members
of the Company&#146;s board of directors (collectively referred to as the &#147;Board&#148; or the &#147;Individual Defendants&#148; and, together with Tilray, the &#147;Defendants&#148;) for their violations of Sections 14(a) and 20(a) of the
Securities Exchange Act of 1934 (&#147;Exchange Act&#148;), 15 U.S.C. &#167;&#167; 78n(a), 78t(a) and Rule <FONT STYLE="white-space:nowrap">14a-9,</FONT> 17 C.F.R. &#167; <FONT STYLE="white-space:nowrap">240.14a-9.</FONT> Plaintiff&#146;s claims
arise in connection with the proposed merger between the Company and Aphria Inc. (&#147;Aphria&#148;) (&#147;Proposed Transaction&#148;). Plaintiff also asserts a claim against the Individual Defendants for breaching their fiduciary duty of
candor/disclosure under state law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2. On December&nbsp;15, 2020, Tilray and Aphria entered into an arrangement agreement
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">that was later amended on February&nbsp;19, 2021 (&#147;Arrangement Agreement&#148;),
whereby Aphria shareholders will be entitled to receive 0.8381 of a share of Tilray common stock for each share of Aphria common stock they hold (&#147;Merger Consideration&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3. Upon consummation of the Proposed Transaction, Aphria shareholders will own 61.2% of the outstanding Tilray common stock,
while Tilray shareholders will only own 38.8%. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4. On March&nbsp;12, 2021, in order to convince Tilray&#146;s public common
shareholders to vote in favor of the Proposed Transaction, the Defendants authorized the filing of a materially incomplete and misleading Definitive Proxy Statement (&#147;Proxy&#148;) with the SEC, in violation of Sections 14(a) and 20(a) of the
Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5. In particular, the Proxy contains materially incomplete and misleading information concerning:
(i)&nbsp;the financial projections;<B> </B>and<B> </B>(ii)&nbsp;the valuation analyses performed by the Company&#146;s financial advisors, Cowen and Company, LLC (&#147;Cowen&#148;) and Imperial Capital, LLC (&#147;Imperial&#148;).<B> </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6. The special meeting of Tilray&#146;s shareholders to vote on the Proposed Transaction will be held on April&nbsp;14, 2021
(&#147;Shareholder Vote&#148;). Therefore, it is imperative that the material information that has been omitted from the Proxy is disclosed prior to the Shareholder Vote, so Tilray&#146;s shareholders can properly exercise their corporate voting
rights. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7. For these reasons, and as set forth in detail herein, Plaintiff asserts claims against Defendants for
violations of Sections 14(a) and 20(a) of the Exchange Act and Rule <FONT STYLE="white-space:nowrap">14a-9.</FONT> Plaintiff seeks to enjoin Defendants from taking any steps to consummate the Proposed Transaction, unless and until the material
information discussed below is disclosed to Tilray&#146;s shareholders sufficiently before the Shareholder Vote or, in the event the Proposed Transaction is consummated, to recover damages resulting from the Defendants&#146; violations of the
Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>JURISDICTION AND VENUE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8. This Court has jurisdiction over all claims asserted herein pursuant to Section&nbsp;27 of the 1934 Act because the claims
asserted herein arise under Sections 14(a) and 20(a) of the 1934 Act and Rule <FONT STYLE="white-space:nowrap">14a-9.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">9. Personal jurisdiction exists over each Defendant either because the Defendant conducts business in or maintains operations
in this District, or is an individual who is either present in this District for jurisdictional purposes or has sufficient minimum contacts with this District as to render the exercise of jurisdiction over each Defendant by this Court permissible
under the traditional notions of fair play and substantial justice. &#147;Where a federal statute such as Section&nbsp;27 of the [Exchange] Act confers nationwide service of process, the question becomes whether the party has sufficient contacts
with the United States, not any particular state.&#148; <I>Sec. Inv&#146;r Prot. Corp. v. Vigman</I>, 764 F.2d 1309, 1315 (9th Cir. 1985). &#147;[S]o long as a defendant has minimum contacts with the United States, Section&nbsp;27 of the Act confers
personal jurisdiction over the defendant in any federal district court.&#148; <I>Id.</I> at 1316. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10. Venue is proper in
this District under Section&nbsp;27 of the Exchange Act, 15 U.S.C. &#167; 78aa, as well as 28 U.S.C. &#167; 1391, because Defendants are found or are inhabitants or transact business in this District. Indeed, Tilray&#146;s common stock trades on the
NasdaqGS, which is headquartered in this District. <I>See, e.g., United States v. Svoboda</I>, 347 F.3d 471, 484 n.13 (2d Cir. 2003) (collecting cases). Additionally, Cowen is located in this District at 599 Lexington Avenue, New York, NY 10022.
</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>PARTIES </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11. Plaintiff is, and has been continuously throughout all times relevant hereto, the owner of Tilray common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12. Defendant Tilray is a public company incorporated under the laws of
Delaware with principal executive offices located at 1100<B> </B>Maughan Road, Nanaimo, BC, Canada, V9X IJ2. Tilray&#146;s common stock trades on the NasdaqGS under the ticker symbol &#147;TLRY.&#148; <B></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">13. Defendant Brendan Kennedy is, and has been at all relevant times, a director of the Company, and Chief Executive Officer.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">14. Defendant Christine St.Clare is, and has been at all relevant times, a director of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">15. Defendant Rebekah Dopp is, and has been at all relevant times, a director of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">16. Defendant Michael Auerbach is, and has been at all relevant times, a director of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">17. Defendant Soren Schroder is, and has been at all relevant times, a director of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">18. Defendants identified in paragraphs 13 through 17 are collectively referred to herein as the &#147;Board&#148; or the
&#147;Individual Defendants,&#148; and together with the Company, the &#147;Defendants.&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SUBSTANTIVE ALLEGATIONS </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>I.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Background of the Company, Aphria, and the Proposed Transaction </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">19. Tilray engages in the research, cultivation, processing, and distribution of medical cannabis. The Company offers its
products to patients, physicians, clinics, pharmacies, governments, and hospitals; and for researchers for commercial purposes, as well as compassionate access and clinical research applications. It operates in Argentina, Australia, Canada, Chile,
Croatia, Cyprus, Germany, Israel, New Zealand, Portugal, Spain, Africa, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Switzerland, the United States, Malta, and the United Kingdom. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">20. Aphria cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. It
offers pharmaceutical-grade medical cannabis, <FONT STYLE="white-space:nowrap">adult-use</FONT> cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P&#146;tite Pof, and Broken Coast
brands. Aphria serves patients and consumers through distributors and online. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">21. According to the December&nbsp;16, 2020,
joint press release announcing the Proposed Transaction: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APHRIA AND TILRAY COMBINE TO CREATE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LARGEST GLOBAL CANNABIS COMPANY WITH PRO FORMA </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REVENUE OF C$874 MILLION (US$685 MILLION) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><U>Leamington, Ontario and Nanaimo, British Columbia &#150; December&nbsp;16, 2020</U> &#150; Aphria Inc.
(&#147;<B>Aphria</B>&#148;) (TSX: <B>APHA </B>and Nasdaq: <B>APHA</B>), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, and Tilray, Inc. (&#147;<B>Tilray</B>&#148;) (Nasdaq:
<B>TLRY</B>), a global pioneer in cannabis research, cultivation, production and distribution, today announced that they have entered into a definitive agreement (the &#147;<B>Agreement</B>&#148;) to combine their businesses and create the
world&#146;s largest global cannabis company (the &#147;<B>Combined Company&#148;</B>) based on pro forma revenue1. The deal is pursuant to a plan of arrangement (the &#147;<B>Arrangement</B>&#148;) under the <I>Business Corporations Act</I>
(Ontario), and the implied pro forma equity value of the Combined Company is approximately C$5.0&nbsp;billion (US$3.9 billion), based on the share price of Aphria and Tilray at the close of market on December&nbsp;15, 2020. Following the completion
of the Arrangement, the Combined Company will have principal offices in the United States (New York and Seattle), Canada (Toronto, Leamington and Vancouver Island), Portugal and Germany, and it will<B> </B>operate under the Tilray corporate name
with shares trading on NASDAQ under ticker symbol &#147;TLRY&#148;. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Combined Company, supported by <FONT
STYLE="white-space:nowrap">low-cost,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> cultivation, processing, and manufacturing facilities, will have a
complete portfolio of branded Cannabis 2.0 products in Canada. Internationally, the Combined Company will be well-positioned to pursue growth opportunities with Aphria&#146;s medical cannabis and distribution footprint in Germany, and Tilray&#146;s
European Union Good Manufacturing Practices (&#147;<B><FONT STYLE="white-space:nowrap">EU-GMP</FONT></B>&#148;) <FONT STYLE="white-space:nowrap">low-cost</FONT> cannabis production facility in Portugal, which has export capabilities and tariff-free
access to the European Union (&#147;<B>EU</B>&#148;) to meet increasing global demand for medical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
cannabis. In the United States, the Combined Company will have a strong consumer packaged goods presence and infrastructure with two strategic pillars, including SweetWater Brewing Company
(&#147;<B>SweetWater</B>&#148;), a cannabis lifestyle branded craft brewer, and Manitoba Harvest, a leading hemp food manufacturer and a pioneer in branded CBD and wellness products. The Combined Company is expected to have a strong, flexible
balance sheet, cash balance and access to capital giving it the ability to accelerate growth and deliver attractive returns for stockholders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the terms of the Arrangement, the shareholders of Aphria (the &#147;<B>Aphria Shareholders</B>&#148;) will receive 0.8381
shares (the &#147;<B>Exchange Ratio</B>&#148;)<B> </B>of Tilray for each Aphria common share (each, an &#147;<B>Aphria Share</B>&#148;), while holders of Tilray shares (the &#147;<B>Tilray Stockholders</B>&#148;) will continue to hold their Tilray
shares (the &#147;<B>Tilray Shares</B>&#148;) with no adjustment to their holdings. Upon the completion of the Arrangement, Aphria Shareholders will own approximately 62&nbsp;percent of the outstanding Tilray Shares on a fully diluted basis,
resulting in a reverse acquisition of Tilray, representing a premium of 23&nbsp;percent based on the share price at market close on December&nbsp;15, 2020 to Tilray shareholders. On a pro forma basis for the last twelve months reported by each
company, the Combined Company would have had revenue of C$874&nbsp;million (US$685 million). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(Emphasis in original). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">22. The Merger Consideration represents inadequate compensation for the Company&#146;s shareholders because under the original
deal structure from February&nbsp;14, 2020, Tilray&#146;s shareholders were to own 56% of the combined company, whereas under the Merger Consideration now, the Company&#146;s shareholders will own only 38.8%. Proxy, 48, 62. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">23. Therefore, it is imperative that the Company&#146;s shareholders receive the material information (discussed in detail
below) that Defendants have omitted from the Proxy, necessary for them to properly exercise their corporate suffrage rights and cast an informed vote on the Proposed Transaction. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>II.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>The Proxy Omits Material Information </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">24. Defendants filed a materially incomplete and misleading Proxy with the SEC, despite the Individual Defendants being
obligated to carefully review the Proxy before it was filed with the SEC and disseminated to the Company&#146;s shareholders, to ensure that it did not contain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
any material misrepresentations or omissions. Thus, the Proxy should be amended prior to the Shareholder Vote, so the Company&#146;s shareholders can make an informed voting decision in
connection with the Proposed Transaction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">25. First, the Proxy fails to disclose material information regarding the
financial projections. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">26. To start, the Proxy omits crucial information regarding the following five sets of financial
projections disclosed in <I>Certain Tilray Forecasts </I>(section of the Proxy): (1) Tilray Management Financial Projections; (2)&nbsp;Aphria Management Projections used by Cowen; (3)&nbsp;Tilray Adjusted Aphria Management Projections used by Cowen;
(4)&nbsp;Aphria Management Projections used by Imperial; and (5)&nbsp;Certain Pro Forma Projections used by Imperial. Proxy, 90-94. In each of these five sets of projections, the Proxy fails to disclose the figures underlying the inputs used to
calculate EBIT, Adjusted EBITDA, and Unlevered Free Cash Flow (&#147;UFCF&#148;). <I>Id. </I>The importance of disclosing these figures is highlighted in the Tilray Management Financial Projections, where Cowen and Imperial used two separate methods
to calculate UFCF, which resulted in significant differences in their view of the Company&#146;s UFCF for fiscal years 2020 through 2023. <I>Id. </I>at 92. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">27. Additionally, the Proxy fails to disclose Net Income projections, despite the five sets of projections above referencing
use of Net Income in calculating EBIT and Adjusted EBITDA. <I>Id. </I>at <FONT STYLE="white-space:nowrap">90-94.</FONT> By disclosing certain projections in the Proxy and withholding the Net Income projections, Defendants render the projections on
pages 90 to 94 of the Proxy materially incomplete and provide a misleading valuation picture of Tilray and Aphria. Simply put, Net Income projections are irreplaceable when it comes to fully, fairly, and accurately understanding a company&#146;s
projections and value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">28. Unlike poker where a player must conceal her unexposed cards, the object
of a proxy statement is to put all of one&#146;s cards on the table <FONT STYLE="white-space:nowrap">face-up.</FONT> In this case, only some of the cards were exposed&#151;the others were concealed. If a proxy statement discloses financial
projections and valuation information, such projections must be complete and accurate. The question here is not the duty to speak, but liability for not having spoken enough. With regard to future events, uncertain figures, and other <FONT
STYLE="white-space:nowrap">so-called</FONT> soft information, a company may choose silence or speech elaborated by the factual basis as then known&#151;but it may not choose half-truths. <I>See Campbell v. Transgenomic, et al.</I>,<I> </I><FONT
STYLE="white-space:nowrap">No.&nbsp;18-2198</FONT> (8th Cir., March&nbsp;1, 2019) (noting that &#147;half-truths&#148; are actionable misrepresentations under securities laws and collecting cases). Accordingly, Defendants must disclose the figures
underlying the inputs used to calculate EBIT, Adjusted EBITDA, and UFCF, and Defendants must also disclose the Net Income projections as well. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">29. Second, the Proxy omits material information regarding Cowen and Imperial&#146;s respective financial analyses for the
Proposed Transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Cowen&#146;s Financial Analyses </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">30. The Proxy discloses that Cowen utilized the Wall Street Projections for both Tilray and Aphria, and the Projected
Synergies prepared by Tilray&#146;s management, in rendering its fairness opinion but neither of these projections are disclosed. Proxy, 78. In fact, for the Projected Synergies, Defendants opted to include a summary over disclosing the actual
projections. <I>Id. </I>at <FONT STYLE="white-space:nowrap">94-95.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">31. With respect to the <I>Analysis of Selected
Publicly-Traded Companies</I>, the Proxy omits the individual multiples observed for each of the selected companies. <I>Id. </I>at <FONT STYLE="white-space:nowrap">79-80.</FONT> Further, the Proxy fails to disclose the inputs and assumptions
underlying Cowen&#146;s selection and application of the following two reference range of multiples: (i) 5.5x to 8.0x; and (ii) 3.0x to 5.0x. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
<I>Id. </I>at 80. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">32. For <I>Tilray&#146;s</I> <I>Discounted Cash
Flow Analysis</I>, the Proxy omits the inputs and assumptions underlying Cowen&#146;s selection of the discount rates ranging from 10.0% to 12.0%, based on an estimate of Tilray&#146;s weighted average cost of capital (&#147;WACC&#148;). <I>Id.
</I>at 81. Moreover, the Proxy fails to disclose the inputs and assumptions underlying the selected Adjusted EBITDA multiples of 15.0x to 20.0x. <I>Id. </I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">33. As for the <I>Aphria Discounted Cash Flow Analysis Based on Aphria Management </I><I>Projections</I>, the Proxy does not
disclose the inputs and assumptions underlying Cowen&#146;s selection of the discount rates ranging from 8.5% to 10.5%, based on an estimate of Aphria&#146;s WACC. <I>Id. </I>Also, the Proxy fails to disclose the inputs and assumptions underlying
the selected Adjusted EBITDA multiples of 15.0x to 20.0x. <I>Id. </I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">34. Similarly, for the <I>Aphria Discounted Cash
Flow Analysis Based on Aphria Management Projections as Adjusted by Tilray Management</I>, the Proxy fails to disclose the inputs and assumptions underlying Cowen&#146;s selection of the discount rates ranging from 8.5% to 10.5%, based on an
estimate of Aphria&#146;s WACC. <I>Id. </I>In addition, the Proxy fails to disclose the inputs and assumptions underlying the selected Adjusted EBITDA multiples of 15.0x to 20.0x. <I>Id.</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">35. These key inputs are material to the Company&#146;s shareholders, and their omission renders the summary of Cowen&#146;s
three Discounted Cash Flow Analyses incomplete and misleading. As one highly-respected law professor explained regarding these crucial inputs, in a discounted cash flow analysis a banker takes management&#146;s forecasts, and then makes several key
choices &#147;each of which can significantly affect the final valuation.&#148; Steven M. Davidoff, Fairness Opinions, 55 Am. U.L. Rev. 1557, 1576 (2006). Such choices include &#147;the appropriate discount rate, and the terminal value&#133;&#148;
<I>Id.</I> As Professor Davidoff explains: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>There is substantial leeway to determine each of these, and any change
can markedly affect the discounted cash flow value. For example, a change in the discount rate by one percent on a stream of cash flows in the billions of dollars can change the discounted cash flow value by tens if not hundreds of millions of
dollars</I>&#133;.This issue arises not only with a discounted cash flow analysis, but with each of the other valuation techniques. <I>This dazzling variability makes it difficult to rely, compare, or analyze the valuations underlying a fairness
opinion </I><B><I>unless full disclosure is made of the various inputs in the valuation process, the weight assigned for each, and the rationale underlying these choices</I></B>. The substantial discretion and lack of guidelines and standards also
makes the process vulnerable to manipulation to arrive at the &#147;right&#148; answer for fairness. This raises a further dilemma in light of the conflicted nature of the investment banks who often provide these opinions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Id.</I> at <FONT STYLE="white-space:nowrap">1577-78</FONT> (emphasis added). Without the above-mentioned information, the
Company&#146;s shareholders cannot evaluate for themselves the reliability of Cowen&#146;s Discounted Cash Flow Analyses, make a meaningful determination of whether the implied equity value ranges reflect the true value of the Company and Aphria, or
were the result of an unreasonable judgment by Cowen, and make an informed decision regarding whether to vote in favor of the Proposed Transaction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">36. Regarding the <I>Current Trading Metrics</I> Analysis, the Proxy omits the Company&#146;s total debt and the number of
shares outstanding as of December&nbsp;14, 2020. Proxy, 83. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">37. Last, the <I>Wall Street Analyst Share Price Targets
</I>Analysis does not disclose the 22 total research analysts Cowen observed, and the individual metrics observed for each of those analysts. <I>Id. </I>at 84. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Imperial&#146;s Financial Analyses </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">38. The Proxy notes that Imperial &#147;reviewed certain publicly available research reports,&#148; yet the Proxy fails to
disclose the sources of those reports.<I> Id. </I>at 85. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">39. For the <I>Comparable Companies Analysis</I>, the Proxy fails
to disclose the individual multiples observed for each of the selected companies. <I>Id. </I>at <FONT STYLE="white-space:nowrap">87-88.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">40. Similarly, for the <I>Precedent Transactions Analysis</I>, the Proxy
does not provide the individual multiples observed by Cowen for each of the selected transactions. <I>Id. </I>at 88. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">41.
As for the<I> Discounted Cash Flow Analysis </I>for both the Company and Aphria, the Proxy omits the following information: (i)&nbsp;the inputs and assumptions underlying Imperial&#146;s application of a range of TEV/EBITDA multiples of 20x to 22x
for Tilray, and 18x to 20x for Aphria; (ii)&nbsp;the inputs and assumptions underlying Imperial&#146;s application of a range of perpetuity growth rates from 8.5% to 9.5%; and (iii)&nbsp;the inputs and assumptions underlying selection of a discount
rate of 12.5%, based upon the WACC for Aphria and Tilray. <I>Id. </I>at 89. The importance of a Discounted Cash Flow Analysis to shareholders is explained above. <I>See </I>paragraph 33. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">42. Finally, regarding the <I>Securities Analysts&#146; Price Targets</I> Analysis, the Proxy fails to disclose the names of
the six equity analysts observed by Imperial. Proxy, 90. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">43. In sum, the omission of the above-referenced information
renders the Proxy materially incomplete and misleading, in contravention of the Exchange Act. Absent disclosure of the foregoing material information prior to the Shareholder Vote concerning the Proposed Transaction, Plaintiff will be unable to make
an informed decision regarding whether to vote her shares in favor of the Proposed Transaction, and she is thus threatened with irreparable harm, warranting the injunctive relief sought herein. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>CAUSES OF ACTION </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COUNT I </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(Against All Defendants for
Violations of Section&nbsp;14(a) of the Exchange Act and Rule <FONT STYLE="white-space:nowrap">14a-9)</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">44.
Plaintiff incorporates each and every allegation set forth above as if fully set forth herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">45. Section&nbsp;14(a)(1)
of the Exchange Act makes it &#147;unlawful for any person, by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
use of the mails or by any means or instrumentality of interstate commerce or of any facility of a national securities exchange or otherwise, in contravention of such rules and regulations as the
Commission may prescribe as necessary or appropriate in the public interest or for the protection of investors, to solicit or to permit the use of his name to solicit any proxy or consent or authorization in respect of any security (other than an
exempted security) registered pursuant to section 78l of this title.&#148; 15 U.S.C. &#167; 78n(a)(1). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">46. Rule <FONT
STYLE="white-space:nowrap">14a-9,</FONT> promulgated by the SEC pursuant to Section&nbsp;14(a) of the Exchange Act, provides that proxy communications shall not contain &#147;any statement which, at the time and in the light of the circumstances
under which it is made, is false or misleading with respect to any material fact, or which omits to state any material fact necessary in order to make the statements therein not false or misleading.&#148; 17 C.F.R. &#167; <FONT
STYLE="white-space:nowrap">240.14a-9.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">47. The omission of information from a proxy will violate Section&nbsp;14(a)
and Rule <FONT STYLE="white-space:nowrap">14a-9</FONT> if other SEC regulations specifically require disclosure of the omitted information.&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">48. Defendants have issued the Proxy with the intention of soliciting the Company&#146;s public common stockholders support for
the Proposed Transaction. Each of the Individual Defendants reviewed and authorized the dissemination of the Proxy, which fails to provide critical information regarding, amongst other things: (i)&nbsp;the financial projections; and (ii)&nbsp;the
valuation analyses performed by Cowen and Imperial, respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">49. In so doing, Defendants made untrue statements of
fact and/or omitted material facts necessary to make the statements made not misleading. Each of the Individual Defendants, by virtue of their roles as officers and/or directors, were aware of the omitted information but failed to disclose such
information, in violation of Section&nbsp;14(a). The Individual Defendants were therefore negligent, as they had reasonable grounds to believe material facts existed that were </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
misstated or omitted from the Proxy, but nonetheless failed to obtain and disclose such information to the Company&#146;s shareholders although they could have done so without extraordinary
effort. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">50. The Individual Defendants knew or were negligent in not knowing that the Proxy is materially misleading and
omits material facts that are necessary to render it not misleading. The Individual Defendants undoubtedly reviewed and relied upon most if not all of the omitted information identified above in connection with their decision to approve and
recommend the Proposed Transaction; indeed, the Proxy states that Cowen and Imperial reviewed and discussed its financial analyses with the Individual Defendants, and further states that the Individual Defendants considered the financial analyses
provided by Cowen and Imperial, as well as their fairness opinions and the assumptions made and matters considered in connection therewith. Further, the Individual Defendants were privy to and had knowledge of the Company&#146;s projections and the
details surrounding the process leading up to the signing of the Arrangement Agreement. The Individual Defendants knew or were negligent in not knowing that the material information identified above has been omitted from the Proxy, rendering the
sections of the Proxy identified above to be materially incomplete and misleading. Indeed, the Individual Defendants were required to, separately, review Cowen and Imperial&#146;s analyses in connection with their receipt of the fairness opinions,
question Cowen and Imperial as to their derivation of fairness, and be particularly attentive to the procedures followed in preparing the Proxy and review it carefully before it was disseminated, to corroborate that there are no material
misstatements or omissions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">51. The Individual Defendants were, at the very least, negligent in preparing and reviewing
the Proxy. The preparation of a proxy statement by corporate insiders containing materially false or misleading statements or omitting a material fact constitutes negligence. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Individual Defendants were negligent in choosing to omit material information from the Proxy or failing to notice the material omissions in the Proxy upon reviewing it, which they were required
to do carefully as the Company&#146;s directors. Indeed, the Individual Defendants were intricately involved in the process leading up to the signing of the Arrangement Agreement, and preparation and review of the Company&#146;s financial
projections. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">52. Tilray is also deemed negligent as a result of the Individual Defendants&#146; negligence in preparing
and reviewing the Proxy. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">53. The misrepresentations and omissions in the Proxy are material to Plaintiff, who will be
deprived of her right to cast an informed vote if such misrepresentations and omissions are not corrected prior to the Shareholder Vote. Plaintiff has no adequate remedy at law. Only through the exercise of this Court&#146;s equitable powers can
Plaintiff be fully protected from the immediate and irreparable injury that Defendants&#146; actions threaten to inflict. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COUNT II
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Against the Individual Defendants for Violations of Section&nbsp;20(a) of the Exchange Act) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">54. Plaintiff incorporates each and every allegation set forth above as if fully set forth herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">55. The Individual Defendants acted as controlling persons of Tilray within the meaning of Section&nbsp;20(a) of the Exchange
Act as alleged herein. By virtue of their positions as officers and/or directors of Tilray, and participation in and/or awareness of the Company&#146;s operations and/or intimate knowledge of the incomplete and misleading statements contained in the
Proxy filed with the SEC, they had the power to influence and control and did influence and control, directly or indirectly, the decision making of the Company, including the content and dissemination of the various statements that Plaintiff
contends are materially incomplete and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
misleading. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">56. Each of the Individual Defendants was provided with
or had unlimited access to copies of the Proxy and other statements alleged by Plaintiff to be misleading prior to and/or shortly after these statements were issued and had the ability to prevent the issuance of the statements or cause the
statements to be corrected. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">57. In particular, each of the Individual Defendants had direct and supervisory involvement in
the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations of the Company, and, therefore, is presumed to have had the power to control or influence the particular transactions giving rise to the
Exchange Act violations alleged herein, and exercised the same. The Proxy contains the unanimous recommendation of each of the Individual Defendants to approve the Proposed Transaction. They were thus directly involved in preparing this document.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">58. In addition, as the Proxy sets forth at length, and as described herein, the Individual Defendants were involved in
negotiating, reviewing, and approving the Arrangement Agreement. The Proxy purports to describe the various issues and information that the Individual Defendants reviewed and considered. The Individual Defendants participated in drafting and/or gave
their input on the content of those descriptions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">59. By virtue of the foregoing, the Individual Defendants have violated
Section&nbsp;20(a) of the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">60. As set forth above, the Individual Defendants had the ability to exercise
control over and did control a person or persons who have each violated Section&nbsp;14(a) and Rule <FONT STYLE="white-space:nowrap">14a-9</FONT> by their acts and omissions as alleged herein. By virtue of their positions as controlling persons,
these Defendants are liable pursuant to Section&nbsp;20(a) of the Exchange Act. As a direct and proximate result of Individual Defendants&#146; conduct, Plaintiff will be irreparably harmed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">61. Plaintiff has no adequate remedy at law. Only through the exercise of
this Court&#146;s equitable powers can Plaintiff be fully protected from the immediate and irreparable injury that Defendants&#146; actions threaten to inflict. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COUNT III </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Against the
Individual Defendants for Breach of Fiduciary Duty of Candor/Disclosure) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">62. Plaintiff incorporates each and every
allegation set forth above as if fully set forth herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">63. By virtue of their role as directors and/or officers of the
Company, the Individual Defendants directly owed Plaintiff and all Company shareholders a fiduciary duty of candor/disclosure, which required them to disclose fully and fairly all material information within their control when they seek shareholder
action, and to ensure that the Proxy did not omit any material information or contain any materially misleading statements. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">64. As alleged herein, the Individual Defendants breached their duty of candor/disclosure by approving or causing the
materially deficient Proxy to be disseminated to Plaintiff and the Company&#146;s other public shareholders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">65. The
misrepresentations and omissions in the Proxy are material, and Plaintiff will be deprived of her right to cast an informed vote if such misrepresentations and omissions are not corrected prior to the Shareholder Vote. Where a shareholder has been
denied one of the most critical rights he or she possesses&#151;the right to a fully informed vote&#151;the harm suffered is an individual and irreparable harm. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">66. Plaintiff has no adequate remedy at law. Only through the exercise of this Court&#146;s equitable powers can Plaintiff be
fully protected from the immediate and irreparable injury that Defendants&#146; actions threaten to inflict. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>PRAYER FOR RELIEF </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREFORE</B>, Plaintiff prays for judgment and relief as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A. Preliminarily enjoining Defendants and all persons acting in concert with them from proceeding with the Shareholder Vote or
consummating the Proposed Transaction, unless and until the Company discloses the material information discussed above which has been omitted from the Proxy; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">B. Directing the Defendants to account to Plaintiff for all damages sustained as a result of their wrongdoing; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">C. Awarding Plaintiff the costs and disbursements of this action, including reasonable attorneys&#146; and expert fees and
expenses; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">D. Granting such other and further relief as this Court may deem just and proper. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>JURY DEMAND </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Plaintiff demands a trial by jury on all issues so triable. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Dated: March&nbsp;23, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><B>MONTEVERDE&nbsp;&amp; ASSOCIATES PC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>/s/ </I>Juan E. Monteverde</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Juan E. Monteverde <FONT STYLE="white-space:nowrap">(JM-8169)</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Empire State Building</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">350 Fifth Avenue, Suite 4405</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">New York, NY 10118</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Tel: (212) <FONT STYLE="white-space:nowrap">971-1341</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Fax: (212) <FONT STYLE="white-space:nowrap">202-7880</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Email: jmonteverde@monteverdelaw.com</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Attorneys for Plaintiff</I></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>d117514dex993.htm
<DESCRIPTION>EX-99.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.3 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Daniel Sadeh, Esq. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>HALPER SADEH LLP </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">667 Madison Avenue, 5th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10065 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone: (212) <FONT STYLE="white-space:nowrap">763-0060</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Facsimile: (646) <FONT STYLE="white-space:nowrap">776-2600</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Email: sadeh@halpersadeh.com </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Counsel for Plaintiff </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES DISTRICT COURT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EASTERN DISTRICT OF NEW YORK </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="52%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">ARTHUR REVELES,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Case No:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">Plaintiff,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">v.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;COMPLAINT
FOR VIOLATION OF</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THE FEDERAL
SECURITIES LAWS</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">TILRAY, INC., BRENDAN KENNEDY,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;JURY TRIAL DEMANDED</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">CHRISTINE ST. CLARE, REBEKAH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">DOPP, SOREN SCHRODER, and</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">MICHAEL AUERBACH,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" STYLE="BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">Defendants.</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Plaintiff Arthur Reveles (&#147;Plaintiff&#148;), by Plaintiff&#146;s undersigned attorneys,
for Plaintiff&#146;s complaint against Defendants (defined below), alleges the following based upon personal knowledge as to Plaintiff and Plaintiff&#146;s own acts, and upon information and belief as to all other matters, based upon, <I>inter
alia,</I> the investigation conducted by and through Plaintiff&#146;s attorneys. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>NATURE OF THE ACTION </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">1. This is an action against Tilray, Inc.<B> </B>(&#147;Tilray&#148; or the &#147;Company&#148;) and its Board of Directors
(the &#147;Board&#148; or the &#147;Individual Defendants&#148;) for their violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 (the &#147;Exchange Act&#148;), 15 U.S.C. &#167;&#167; 78n(a) and 78t(a), and Rule <FONT
STYLE="white-space:nowrap">14a-9</FONT> promulgated thereunder by the SEC, 17 C.F.R. &#167; <FONT STYLE="white-space:nowrap">240.14a-9,</FONT> in connection with Tilray&#146;s proposed merger (the &#147;Proposed Transaction&#148;) with Aphria Inc.
(&#147;Aphria&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">2. In connection with the Proposed Transaction, shareholders of Aphria will
receive 0.8381 shares of Tilray common stock for each Aphria share held. Tilray stockholders will continue to hold their Tilray common stock, which will remain outstanding. Upon the completion of the Proposed Transaction, it is expected that the
exchange ratio will result in shareholders of each of Aphria and of Tilray owning approximately 61.2% and 38.8%, respectively, of the post-closing outstanding Tilray common stock (on a fully diluted basis). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">3. On March&nbsp;12, 2021, Defendants caused to be filed with the SEC a Schedule 14A Definitive Proxy Statement (the
&#147;Proxy Statement&#148;) under the Exchange Act in connection with the Proposed Transaction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">4. The Proxy Statement,
which recommends that Tilray shareholders vote in favor of, among other things, the issuance of Tilray common stock in connection with the Proposed Transaction (the &#147;Stock Issuance&#148;), omits and/or misrepresents material information
concerning: (1)&nbsp;Tilray&#146;s and Aphria&#146;s financial projections; (2)&nbsp;the financial analyses performed by Tilray&#146;s financial advisors, Cowen and Company, LLC (&#147;Cowen&#148;) and Imperial Capital, LLC (&#147;Imperial&#148;),
in connection with their fairness opinions; (3)&nbsp;potential conflicts of interest involving Imperial; and (4)&nbsp;potential conflicts of interest involving Company insiders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">5. These material misrepresentations and omissions prevent the Company&#146;s shareholders from making a fully informed voting
decision on the Stock Issuance proposal before the April&nbsp;16, 2021 shareholder vote. Accordingly, the Company&#146;s shareholders will be irreparably harmed if these material misrepresentations and omissions are not remedied before the
anticipated shareholder vote on the Stock Issuance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>JURISDICTION AND VENUE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">6. The claims asserted herein arise under and pursuant to Sections 14(a) and 20(a) of the Exchange Act (15 U.S.C. &#167;&#167;
78n(a) and 78t(a)) and Rule <FONT STYLE="white-space:nowrap">14a-9</FONT> promulgated thereunder by the SEC (17 C.F.R. &#167; <FONT STYLE="white-space:nowrap">240.14a-9).</FONT> <B></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">7. This Court has jurisdiction over the subject matter of this action pursuant to 28 U.S.C. &#167; 1331, and Section&nbsp;27 of
the Exchange Act, 15 U.S.C. &#167; 78aa. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">8. Venue is proper in this District pursuant to 28 U.S.C. &#167; 1391(b) and
Section&nbsp;27 of the Exchange Act (15 U.S.C. &#167; 78aa(c)) as a substantial portion of the transactions and wrongs complained of herein had an effect in this District, and the alleged misstatements entered and the subsequent damages occurred in
this District. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">9. In connection with the acts, conduct and other wrongs alleged in this complaint, Defendants, directly or
indirectly, used the means and instrumentalities of interstate commerce, including but not limited to, the United States mails, interstate telephone communications and the facilities of the national securities exchange. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>PARTIES </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">10. Plaintiff is, and has been at all relevant times hereto, an owner of Tilray common stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">11. Defendant Tilray engages in the research, cultivation, processing, and distribution of medical cannabis. The Company is
incorporated in Delaware. The Company&#146;s common stock trades on the NASDAQ under the ticker symbol, &#147;TLRY.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">12. Defendant Brendan Kennedy (&#147;Kennedy&#148;) is Chief Executive Officer and a director of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">13. Defendant Christine St. Clare (&#147;St. Clare&#148;) is a director of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">14. Defendant Rebekah Dopp (&#147;Dopp&#148;) is a director of the Company.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">15. Defendant Soren Schroder (&#147;Schroder&#148;) is a director of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">16. Defendant Michael Auerbach (&#147;Auerbach&#148;) is a director of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">17. Defendants Kennedy, St. Clare, Dopp, Schroder, and Auerbach are collectively referred to herein as the &#147;Individual
Defendants.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">18. Defendants Tilray and the Individual Defendants are collectively referred to herein as the
&#147;Defendants.&#148;<B> </B> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SUBSTANTIVE ALLEGATIONS </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B>A. The Proposed Transaction </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">19. On December&nbsp;16, 2020, Tilray and Aphria issued a press release announcing the Proposed Transaction, stating in
pertinent part: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Aphria and Tilray Combine to Create Largest Global Cannabis Company </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>With Pro Forma Revenue of C$874 Million (US$685 Million) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Complementary, Scalable Medical and <FONT STYLE="white-space:nowrap">Adult-Use</FONT> Cannabis Businesses Strengthen
Leadership Position in Canada; Expands U.S. and International Reach through World-Class Cultivation, Manufacturing, Diversified Product Portfolio and Distribution Footprint</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Robust Supply Chain and Operational Efficiencies Expected to Generate Approximately C$100 Million of <FONT
STYLE="white-space:nowrap">Pre-Tax</FONT> Annual Cost Synergies </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Aphria and Tilray to Host a Conference Call and Webcast at 8:30
a.m. Eastern Time </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">December&nbsp;16, 2020 07:00 AM Eastern Standard Time </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">LEAMINGTON, Ontario&nbsp;&amp; NANAIMO, British Columbia&#151;(BUSINESS WIRE)&#151;Aphria Inc.
(&#147;<B>Aphria</B>&#148;) (TSX: <B>APHA </B>and Nasdaq: <B>APHA),</B> a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, and Tilray, Inc. (&#147;<B>Tilray</B>&#148;) (Nasdaq:
<B>TLRY),</B> a global pioneer in cannabis research, cultivation, production and distribution, today announced that they have entered into a definitive agreement (the &#147;<B>Agreement</B>&#148;) to combine their businesses and create the
world&#146;s largest global cannabis company (the &#147;<B>Combined</B><B> Company&#148;)</B> based on pro forma revenue<SUP STYLE="font-size:85%; vertical-align:top">1</SUP>. The deal is pursuant to a plan of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">arrangement (the &#147;<B>Arrangement</B>&#148;) under the
<I>Business Corporations Act</I> (Ontario), and the implied pro forma equity value of the Combined Company is approximately C$5.0&nbsp;billion (US$3.9 billion), based on the share price of Aphria and Tilray at the close of market on
December&nbsp;15, 2020. Following the completion of the Arrangement, the Combined Company will have principal offices in the United States (New York and Seattle), Canada (Toronto, Leamington and Vancouver Island), Portugal and Germany, and it
will<B> </B>operate under the Tilray corporate name with shares trading on NASDAQ under ticker symbol &#147;TLRY&#148;. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Combined Company, supported by <FONT STYLE="white-space:nowrap">low-cost,</FONT> <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> cultivation, processing, and manufacturing facilities, will have a complete portfolio of branded Cannabis 2.0 products
in Canada. Internationally, the Combined Company will be well-positioned to pursue growth opportunities with Aphria&#146;s medical cannabis and distribution footprint in Germany, and Tilray&#146;s European Union Good Manufacturing Practices
(&#147;<B><FONT STYLE="white-space:nowrap">EU-GMP</FONT></B>&#148;) <FONT STYLE="white-space:nowrap">low-cost</FONT> cannabis production facility in Portugal, which has export capabilities and tariff-free access to the European Union
(&#147;<B>EU</B>&#148;) to meet increasing global demand for medical cannabis. In the United States, the Combined Company will have a strong consumer packaged goods presence and infrastructure with two strategic pillars, including SweetWater Brewing
Company (&#147;<B>SweetWater</B>&#148;), a cannabis lifestyle branded craft brewer, and Manitoba Harvest, a leading hemp food manufacturer and a pioneer in branded CBD and wellness products. The Combined Company is expected to have a strong,
flexible balance sheet, cash balance and access to capital giving it the ability to accelerate growth and deliver attractive returns for stockholders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the terms of the Arrangement, the shareholders of Aphria (the &#147;<B>Aphria</B><B>
Shareholders&#148;)</B> will receive 0.8381 shares (the &#147;<B>Exchange</B><B> Ratio&#148;) </B>of Tilray for each Aphria common share (each, an &#147;<B>Aphria</B><B> Share&#148;),</B> while holders of Tilray shares (the &#147;<B>Tilray</B><B>
Stockholders&#148;)</B> will continue to hold their Tilray shares (the &#147;<B>Tilray</B><B> Shares&#148;)</B> with no adjustment to their holdings. Upon the completion of the Arrangement, Aphria Shareholders will own approximately 62&nbsp;percent
of the outstanding Tilray Shares on a fully diluted basis, resulting in a reverse acquisition of Tilray, representing a premium of 23&nbsp;percent based on the share price at market close on December&nbsp;15, 2020 to Tilray shareholders. On a pro
forma basis for the last twelve months reported by each company, the Combined Company would have had revenue of C$874&nbsp;million (US$685 million). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman"><B>Proven Leadership Team </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Combined Company will be led by a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> management team and board of directors, with strong track records in consumer-packaged goods and cannabis experience internationally. Upon completion of
the Arrangement, Aphria&#146;s current Chairman and Chief Executive Officer, Irwin D. Simon, will lead the Combined Company as Chairman and Chief Executive Officer. The board of directors will consist of nine members, seven of which, including
Mr.&nbsp;Simon, are current Aphria directors and two of which will be from Tilray, including Brendan Kennedy, and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
one of which is to be designated. Aphria and Tilray are confident that the leadership team and proposed board of directors of the Combined Company provides a strong foundation for the Combined
Company to accelerate growth. Additional senior leadership positions at the Combined Company will be named at a later date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-right:4%; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;* </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman"><B>Agreement Details </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Under the terms of the Agreement, the Arrangement will be carried out by way of a court approved plan of
arrangement under the <I>Business Corporations Act</I> (Ontario) and will require the approval of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the votes cast by the Aphria Shareholders at a special meeting. Approval of a majority
of the votes cast by Tilray stockholders will be required to, among other things contemplated by the Agreement, authorize the issuance of Tilray shares to Aphria shareholders pursuant to the Arrangement. Following completion of the Arrangement,
Aphria will become a wholly-owned subsidiary of Tilray, with Aphria shareholders owning approximately 62&nbsp;percent of Tilray. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Completion of the Arrangement is subject to regulatory and court approvals and other customary closing
conditions. Regulatory approvals expected to be required include Competition Bureau (Canada), U.S. HSR and Germany FDI. The Agreement includes certain reciprocal customary provisions, including covenants in respect of the <FONT
STYLE="white-space:nowrap">non-solicitation</FONT> of alternative transactions, a right to match superior proposals and C$65<B></B>&nbsp;million (US$50 million) reciprocal termination fee payable under certain circumstances. The Arrangement is
expected to close in the second quarter of calendar year 2021 following the receipt of such regulatory approvals, as well as court approval of the Arrangement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each of Aphria&#146;s and Tilray&#146;s respective directors and officers and certain principal Tilray
Stockholders have entered into voting support agreements agreeing to vote their Aphria Shares or Tilray Shares, as applicable, in favor of the resolutions put before them pursuant to the Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For further information on the terms and conditions of the Arrangement, please refer to the Agreement in its
entirety, which will be available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Full details of the Arrangement will be included in a management information circular of Aphria and in a proxy statement of Tilray to be delivered to Aphria
Shareholders and the Tilray Stockholders, respectively, in the coming weeks. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman"><B>Board of Directors&#146; Approval
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Each of Aphria&#146;s and Tilray&#146;s respective board of directors has unanimously approved the
Agreement and the Arrangement. Jefferies LLC provided a fairness opinion to the Board of Directors of Aphria on December&nbsp;15, 2020, stating that, as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
of the date of such opinion and based upon the scope of review and subject to the assumptions, limitations and qualifications stated in such opinion, the Exchange Ratio is fair, from a financial
point of view, to the Aphria Shareholders. Cowen provided a fairness opinion dated December&nbsp;15, 2020 to the board of directors of Tilray stating that, as of the date of such opinion and based upon and subject to the assumptions, limitations and
qualifications stated in such opinion, the Exchange Ratio is fair, from a financial point of view, to Tilray. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman"><B>Advisors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Jefferies LLC is serving as financial advisor and DLA Piper LLP (US), DLA Piper (Canada) LLP and Fasken
Martineau Dumoulin LLP are acting as legal counsel to Aphria. Cowen is serving as financial advisor and Cooley LLP and Blake, Cassels and Graydon LLP are acting as legal counsel to Tilray. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-right:4%; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;* </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman"><B>About Aphria Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Aphria Inc. is a leading global cannabis company inspiring and empowering the worldwide community to live
their very best life. Headquartered in Leamington, Ontario &#150; the greenhouse capital of Canada &#150; Aphria Inc. has been setting the standard for the <FONT STYLE="white-space:nowrap">low-cost</FONT> production of high-quality cannabis at
scale, grown in the most natural conditions possible. Focusing on untapped opportunities and backed by the latest technologies, Aphria Inc. is committed to bringing breakthrough innovation to the global cannabis market. The Company&#146;s portfolio
of brands is grounded in expertly researched consumer insights designed to meet the needs of every consumer segment. Rooted in our founders&#146; multi-generational expertise in commercial agriculture, Aphria Inc. drives sustainable long-term
shareholder value through a diversified approach to innovation, strategic partnerships, and global expansion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For more information, visit: aphriainc.com </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman"><B>About Tilray<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Tilray (Nasdaq: TLRY) is a global pioneer in the research, cultivation, production and distribution of
cannabis and cannabinoids currently serving tens of thousands of patients and consumers in 15 countries spanning five continents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>B. The Proxy Statement Contains Materially False and Misleading Statements and Omissions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">20. The Proxy Statement omits and/or misrepresents material information concerning: (1) Tilray&#146;s and Aphria&#146;s
financial projections; (2)&nbsp;the financial analyses performed by Tilray&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
financial advisors in connection with their fairness opinions; (3)&nbsp;potential conflicts of interest involving Imperial; and (4)&nbsp;potential conflicts of interest involving Company
insiders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">21. The omission of the material information (referenced below) renders the following sections of the Proxy
Statement false and misleading, among others: (i)&nbsp;Our Reasons for the Arrangement; (ii)&nbsp;Recommendation of the Tilray Board; (iii)&nbsp;Opinion of Tilray&#146;s Financial Advisors; (iv)&nbsp;Certain Tilray Forecasts; and (v)&nbsp;Aphria
Unaudited Financial Projections. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">22. Unless and until the material misstatements and omissions (referenced below) are
remedied before the April&nbsp;16, 2021 shareholder vote, the Company&#146;s shareholders will be forced to make a voting decision on the Stock Issuance without full disclosure of all material information. In the event Defendants fail to disclose
the following information before the shareholder vote, Plaintiff may seek to recover damages resulting from Defendants&#146; misconduct. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1. Material Omissions Concerning Tilray&#146;s and Aphria&#146;s Financial Projections </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">23. The Proxy Statement fails to disclose information concerning Tilray&#146;s and Aphria&#146;s financial projections. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">24. With respect to the &#147;Tilray Management Financial Projections,&#148; the Proxy Statement fails to disclose the
following: (1)&nbsp;all line items underlying (i)&nbsp;Revenue, (ii) <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> GAAP Gross Profit, (iii)&nbsp;EBIT, (iv) Adjusted EBITDA, (v)&nbsp;Unlevered Free Cash Flow (calculated by Cowen), and
(vi)&nbsp;Unlevered Free Cash Flow (calculated by Imperial); (2) Tilray&#146;s net income projections; and (3)&nbsp;a reconciliation of all <FONT STYLE="white-space:nowrap">non-GAAP</FONT> to GAAP financial metrics. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">25. With respect to the &#147;Aphria Management Projections used by Cowen,&#148; the Proxy Statement fails to disclose the
following: (1)&nbsp;all line items underlying (i)&nbsp;Revenue, (ii) <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Gross Profit, (iii)&nbsp;EBIT, (iv) Adjusted EBITDA, and (v)&nbsp;Unlevered Free Cash Flow; (2)&nbsp;Aphria&#146;s net income
projections; and (3)&nbsp;a reconciliation of all <FONT STYLE="white-space:nowrap">non-GAAP</FONT> to GAAP financial metrics. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">26. With respect to the &#147;Tilray Adjusted Aphria Management Projections used by
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
Cowen,&#148; the Proxy Statement fails to disclose the following: (1)&nbsp;all line items underlying (i)&nbsp;Revenue, (ii) <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Gross Profit,
(iii)&nbsp;EBIT, (iv) Adjusted EBITDA, and (v)&nbsp;Unlevered Free Cash Flow; (2)&nbsp;Aphria&#146;s net income projections; and (3)&nbsp;a reconciliation of all <FONT STYLE="white-space:nowrap">non-GAAP</FONT> to GAAP financial metrics. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">27. With respect to the &#147;Aphria Management Projections used by Imperial,&#148; the Proxy Statement fails to disclose the
following: (1)&nbsp;all line items underlying (i)&nbsp;Revenue, (ii) <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Gross Profit, (iii)&nbsp;Adjusted EBITDA, and (iv)&nbsp;Unlevered Free Cash Flow; (2)&nbsp;Aphria&#146;s net income projections;
and (3)&nbsp;a reconciliation of all <FONT STYLE="white-space:nowrap">non-GAAP</FONT> to GAAP financial metrics. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">28. With
respect to the &#147;Certain Pro Forma Projections used by Imperial,&#148; the Proxy Statement fails to disclose the following: (1)&nbsp;all line items underlying (i)&nbsp;Revenue, (ii) <FONT STYLE="white-space:nowrap">Non-GAAP</FONT> Gross Profit,
(iii)&nbsp;Adjusted EBITDA, and (iv)&nbsp;Unlevered Free Cash Flow; (2)&nbsp;the combined company&#146;s net income projections; and (3)&nbsp;a reconciliation of all <FONT STYLE="white-space:nowrap">non-GAAP</FONT> to GAAP financial metrics. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">29. With respect to the &#147;Summary of the Financial Projections by Aphria,&#148; the Proxy Statement fails to disclose the
following: (1)&nbsp;all line items underlying (i)&nbsp;Net Revenue, (ii)&nbsp;Gross Profit, and (iii)&nbsp;Adjusted EBITDA excluding NCI; (2)&nbsp;Aphria&#146;s net income projections; and (3)&nbsp;a reconciliation of all <FONT
STYLE="white-space:nowrap">non-GAAP</FONT> to GAAP financial metrics. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">30. With respect to the &#147;Summary of the Tilray
Financial Projections by Aphria,&#148; the Proxy Statement fails to disclose the following: (1)&nbsp;all line items underlying (i)&nbsp;Net Revenue, (ii)&nbsp;Gross Profit, and (iii)&nbsp;Adjusted EBITDA; (2)&nbsp;Tilray&#146;s net income
projections; and (3)&nbsp;a reconciliation of all <FONT STYLE="white-space:nowrap">non-GAAP</FONT> to GAAP financial metrics. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">31. When a company discloses <FONT STYLE="white-space:nowrap">non-GAAP</FONT> financial metrics in a Proxy Statement, the
company must also disclose all projections and information necessary to make the <FONT STYLE="white-space:nowrap">non-GAAP</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
metrics not misleading, and must provide a reconciliation (by schedule or other clearly understandable method) of the differences between the <FONT STYLE="white-space:nowrap">non-GAAP</FONT>
financial metrics disclosed or released with the most comparable financial metrics calculated and presented in accordance with GAAP. The SEC has increased its scrutiny of a company&#146;s use of <FONT STYLE="white-space:nowrap">non-GAAP</FONT>
financial measures as such measures can be misleading and &#147;crowd out&#148; more reliable GAAP information.<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">32. The disclosure of this information is material because it would provide the Company&#146;s shareholders with a basis to
project the future financial performance of the Company and combined company and would allow shareholders to better understand the financial analyses performed by the Company&#146;s financial advisors in support of their fairness opinions.
Shareholders cannot hope to replicate management&#146;s inside view of the future prospects of the Company. Without such information, which is uniquely possessed by Defendant(s) and the Company&#146;s financial advisors, the Company&#146;s
shareholders are unable to determine how much weight, if any, to place on the Company&#146;s financial advisors&#146; fairness opinions in determining whether to vote for or against the Proposed Transaction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">33. The above-referenced omitted information, if disclosed, would significantly alter the total mix of information available to
the Company&#146;s shareholders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>2. Material Omissions Concerning the Financial Advisors&#146; Analyses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">34. In connection with the Proposed Transaction, the Proxy Statement omits material </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Mary Jo White, <I>Keynote Address, International Corporate Governance Network Annual Conference: Focusing
the Lens of Disclosure to Set the Path Forward on Board Diversity, <FONT STYLE="white-space:nowrap">Non-GAAP,</FONT> and Sustainability </I>(June 27, 2016), https://www.sec.gov/news/speech/chair-white-icgn-speech.html (footnotes omitted) (last
visited Mar. 24, 2021) (&#147;And last month, the staff issued guidance addressing a number of troublesome practices which can make <FONT STYLE="white-space:nowrap">non-GAAP</FONT> disclosures misleading: the lack of equal or greater prominence for
GAAP measures; exclusion of normal, recurring cash operating expenses; individually tailored <FONT STYLE="white-space:nowrap">non-GAAP</FONT> revenues; lack of consistency; cherry-picking; and the use of cash per share data. I strongly urge
companies to carefully consider this guidance and revisit their approach to <FONT STYLE="white-space:nowrap">non-GAAP</FONT> disclosures.&#148;). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">information concerning analyses performed by Cowen and Imperial. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">35. The valuation methods, underlying assumptions, and key inputs used by Cowen and Imperial in rendering their purported
fairness opinions must be fairly disclosed to Tilray shareholders. The description of Cowen&#146;s and Imperial&#146;s fairness opinions and analyses, however, fail to include key inputs and assumptions underlying those analyses. Without the
information described below, Tilray shareholders are unable to fully understand Cowen&#146;s and Imperial&#146;s fairness opinions and analyses, and are thus unable to determine how much weight, if any, to place on them in determining whether to
vote for or against the Proposed Transaction. This omitted information, if disclosed, would significantly alter the total mix of information available to the Company&#146;s shareholders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>A. </B><B><I>Cowen&#146;s Analyses </I></B><B> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">36. With respect to Cowen&#146;s &#147;Analysis<I> of Selected Publicly-Traded Companies,&#148;</I> the Proxy Statement fails
to disclose the individual multiples and financial metrics of each company Cowen observed in its analyses. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">37. The Proxy
Statement fails to disclose the following concerning Cowen&#146;s &#147;Tilray <I>Discounted Cash Flow Analysis&#148;:</I> (1) all line items underlying the projected unlevered free cash flows of Tilray for the fiscal years ended December&nbsp;31,
2021 through December&nbsp;31, 2023; (2) the terminal value of Tilray at December&nbsp;31, 2023; (3) the assumptions described by management of Tilray; and (4)&nbsp;the individual inputs and assumptions underlying the (i)&nbsp;discount rates ranging
from 10.0% to 12.0%, and (ii)&nbsp;multiples ranging from 15.0x to 20.0x. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">38. The Proxy Statement fails to disclose the
following concerning Cowen&#146;s &#147;Aphria<I> Discounted Cash Flow Analysis Based on Aphria Management Projections&#148;:</I> (1) all line items underlying the projected unlevered free cash flows of Aphria for the fiscal years ended May&nbsp;31,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
2021 through May&nbsp;31, 2024; (2) the terminal value of Aphria at May&nbsp;31, 2024; (3) the assumptions described by management of Aphria; and (4)&nbsp;the individual inputs and assumptions
underlying the (i)&nbsp;discount rates ranging from 8.5% to 10.5%, and (ii)&nbsp;multiples ranging from 15.0x to 20.0x. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">39. The Proxy Statement fails to disclose the following concerning Cowen&#146;s &#147;Aphria<I> Discounted Cash Flow Analysis
Based on Aphria Management Projections as Adjusted by </I><I>Tilray Management&#148;:</I> (1) all line items underlying the projected unlevered cash flows of Aphria for the portion of the fiscal year from January&nbsp;1, 2021 through May&nbsp;31,
2021 and the fiscal years ended May&nbsp;31, 2022 through May&nbsp;31, 2024; (2) the terminal value of Aphria at May&nbsp;31, 2024; (3) the assumptions described by management of Aphria and Tilray; and (4)&nbsp;the individual inputs and assumptions
underlying the (i)&nbsp;discount rates ranging from 8.5% to 10.5%, and (ii)&nbsp;multiples ranging from 15.0x to 20.0x. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">40. With respect to Cowen&#146;s &#147;Wall<I> Street Analyst Share Price Targets,&#148;</I> the Proxy Statement fails to
disclose: (1)&nbsp;the individual price targets observed by Cowen in its analysis; and (2)&nbsp;the sources thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>B.
</B><B><I>Imperial&#146;s Analyses </I></B><B> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">41. With respect to Imperial&#146;s &#147;Comparable<I> Companies
Analysis&#148;</I> and &#147;Precedent<I> Transactions Analysis,&#148;</I> the Proxy Statement fails to disclose the individual multiples and financial metrics of each company and transaction Imperial observed in its analyses as well as the
transaction values and premiums paid therein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">42. The Proxy Statement fails to disclose the following concerning
Imperial&#146;s &#147;Discounted<I> Cash Flow Analysis&#148;:</I> (1) the terminal values of Tilray and Aphria; (2)&nbsp;the individual inputs and assumptions underlying the (i)&nbsp;multiples of 20x to 22x for Tilray and 18x to 20x for Aphria,
(ii)&nbsp;range of perpetuity growth rates of 8.5% to 9.5%; and (iii)&nbsp;discount rate of 12.5%; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
(3) the net debt of Aphria and Tilray, respectively. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">43. With
respect to Imperial&#146;s &#147;Securities<I> Analysts&#146; Price Targets,&#148;</I> the Proxy Statement fails to disclose: (1)&nbsp;the individual price targets observed by Imperial in its analysis; and (2)&nbsp;the sources thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3. Material Omissions Concerning Potential Conflicts of Interest Involving Imperial</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">44. The Proxy Statement omits material information concerning potential conflicts of interest involving Imperial. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">45. The Proxy Statement provides that &#147;Imperial received a fee ($300,000) prior to the delivery of its opinion, in
addition to other fees ($298,637.50) received for advisory services provided to the Tilray Transaction Committee in connection with the Tilray Transaction Committee&#146;s previous review of Tilray&#146;s potential strategic alternatives.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">46. The Proxy Statement, however, fails to make clear the <B><I>total</I></B> amount of compensation Imperial will receive for
serving as Tilray&#146;s financial advisor in connection with the Proposed Transaction, including the amount of Imperial&#146;s compensation that is contingent upon consummation of the Proposed Transaction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">47. Disclosure of a financial advisor&#146;s compensation and potential conflicts of interest to shareholders is required due
to their central role in the evaluation, exploration, selection, and implementation of strategic alternatives and the rendering of any fairness opinions. Disclosure of a financial advisor&#146;s potential conflicts of interest may inform
shareholders on how much weight to place on that analysis. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">48. The above-referenced omitted information, if disclosed,
would significantly alter the total mix of information available to the Company&#146;s shareholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4. Material Omissions Concerning Company Insiders&#146; Potential Conflicts of
Interest</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">49. The Proxy Statement omits material information concerning potential conflicts of interest involving
Company insiders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">50. The December&nbsp;16, 2020 press release announcing the Proposed Transaction provides that Defendant
Kennedy, who serves as CEO and a director of Tilray, as well as another Tilray director, will serve as directors of the combined company, stating in pertinent part: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B>Proven Leadership Team </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">The Combined Company will be led by a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> management team and board of directors, with strong track records in consumer-packaged goods and cannabis experience internationally. Upon completion of
the Arrangement, Aphria&#146;s current Chairman and Chief Executive Officer, Irwin D. Simon, will lead the Combined Company as Chairman and Chief Executive Officer. <B><I>The board of directors will consist of nine members, seven of which, including
Mr.</I></B><B><I></I></B><B><I>&nbsp;Simon, are current Aphria directors and two of which will be from Tilray, including Brendan Kennedy, and one of which is to be designated. </I></B>Aphria and Tilray are confident that the leadership team and
proposed board of directors of the Combined Company provides a strong foundation for the Combined Company to accelerate growth. Additional senior leadership positions at the Combined Company will be named at a later date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">(emphasis added.) </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">51. The Proxy Statement, however, fails to sufficiently disclose the details of all employment-related and compensation-related
discussions and negotiations concerning the Company&#146;s officers and directors, including the parties to such communications, when they occurred, and the specific content discussed/communicated. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">52. The Proxy Statement further fails to sufficiently disclose the extent to which Aphria&#146;s proposals mentioned management
retention or equity participation in the combined company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">53. Any communications regarding post-transaction employment
during the negotiation of the underlying transaction must be disclosed to shareholders. This information is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
necessary for shareholders to understand potential conflicts of interest of management and the Board. Such information may illuminate the motivations that would prevent fiduciaries from acting
solely in the best interests of the Company&#146;s shareholders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">54. The above-referenced omitted information, if
disclosed, would significantly alter the total mix of information available to the Company&#146;s shareholders. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>COUNT I </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For Violations of Section&nbsp;14(a) and Rule <FONT STYLE="white-space:nowrap">14a-9</FONT> Promulgated Thereunder </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Against All Defendants </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">55. Plaintiff repeats and realleges each and every allegation contained above as if fully set forth herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">56. During the relevant period, Defendants, individually and in concert, directly or indirectly, disseminated or approved the
false and misleading Proxy Statement specified above, which failed to disclose material facts necessary in order to make the statements made, in light of the circumstances under which they were made, not misleading, in violation of
Section&nbsp;14(a) of the Exchange Act and Rule <FONT STYLE="white-space:nowrap">14a-9</FONT> promulgated thereunder by the SEC. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">57. Each of the Individual Defendants, by virtue of his/her positions within the Company as officers and/or directors, were
aware of the omitted information but failed to disclose such information, in violation of Section&nbsp;14(a) of the Exchange Act. Defendants, by use of the mails and means and instrumentalities of interstate commerce, solicited and/or permitted the
use of their names to file and disseminate the Proxy Statement with respect to the Proposed Transaction and/or Stock Issuance. The Defendants were, at minimum, negligent in filing the materially false and misleading Proxy Statement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">58. The false and misleading statements and omissions in the Proxy Statement are material in that a reasonable shareholder
would consider them important in deciding how to vote on the Stock Issuance. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">59. By reason of the foregoing, Defendants have violated Section&nbsp;14(a)
of the Exchange Act and Rule <FONT STYLE="white-space:nowrap">14a-9</FONT> promulgated thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">60. Because of the
false and misleading statements and omissions in the Proxy Statement, Plaintiff is threatened with irreparable harm. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>COUNT II
</U></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Violations of Section&nbsp;20(a) of the Exchange Act </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Against the Individual Defendants </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">61. Plaintiff repeats and realleges each and every allegation contained in the foregoing paragraphs as if fully set forth
herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">62. The Individual Defendants acted as control persons of the Company within the meaning of Section&nbsp;20(a) of
the Exchange Act as alleged herein. By virtue of their senior positions as officers and/or directors of the Company and participation in and/or awareness of the Company&#146;s operations and/or intimate knowledge of the false statements contained in
the Proxy Statement filed with the SEC, they had the power to and did influence and control, directly or indirectly, the decision-making of the Company, including the content and dissemination of the false and misleading Proxy Statement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">63. Each of the Individual Defendants was provided with or had unlimited access to copies of the Proxy Statement and other
statements alleged by Plaintiff to be misleading prior to and/or shortly after these statements were issued and had the ability to prevent the issuance of the statements or cause the statements to be corrected. As officers and/or directors of a
publicly owned company, the Individual Defendants had a duty to disseminate accurate and truthful information with respect to the Proxy Statement, and to correct promptly any public statements issued by the Company which were or had become
materially false or misleading. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">64. In particular, each of the Individual Defendants had direct and supervisory
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">
involvement in the operations of the Company, and, therefore, is presumed to have had the power to control or influence the particular transactions giving rise to the securities violations as
alleged herein, and exercised the same. The Individual Defendants were provided with or had unlimited access to copies of the Proxy Statement and had the ability to prevent the issuance of the statements or to cause the statements to be corrected.
The Proxy Statement at issue contains the recommendation of the Individual Defendants to approve the Proposed Transaction and/or Stock Issuance. Thus, the Individual Defendants were directly involved in the making of the Proxy Statement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">65. In addition, as the Proxy Statement sets forth at length, and as described herein, the Individual Defendants were involved
in negotiating, reviewing, and approving the Proposed Transaction and/or Stock Issuance. The Proxy Statement purports to describe the various issues and information that they reviewed and considered&#151;descriptions which had input from the
Individual Defendants. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">66. By virtue of the foregoing, the Individual Defendants have violated Section&nbsp;20(a) of the
Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">67. As set forth above, the Individual Defendants had the ability to exercise control over and did control a
person or persons who have each violated Section&nbsp;14(a) and Rule <FONT STYLE="white-space:nowrap">14a-9</FONT> promulgated thereunder, by their acts and omissions as alleged herein. By virtue of their positions as controlling persons, the
Individual Defendants are liable pursuant to Section&nbsp;20(a) of the Exchange Act. As a direct and proximate result of Defendants&#146; conduct, the Company&#146;s shareholders will be irreparably harmed. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>PRAYER FOR RELIEF </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREFORE,</B> Plaintiff prays for judgment and relief as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">A. Preliminarily and permanently enjoining Defendants and all persons acting
in concert with them from proceeding with, consummating, or closing the Proposed Transaction and any vote on the Stock Issuance, unless and until Defendants disclose and disseminate the material information identified above to Company shareholders;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">B. In the event Defendants consummate the Proposed Transaction, rescinding it and setting it aside or awarding rescissory
damages; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">C. Declaring that Defendants violated Sections 14(a) and 20(a) of the Exchange Act, and Rule <FONT
STYLE="white-space:nowrap">14a-9</FONT> promulgated thereunder; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">D. Awarding Plaintiff reasonable costs and expenses
incurred in this action, including counsel fees and expert fees; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">E. Granting such other and further relief as the
Court may deem just and proper. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>JURY TRIAL DEMANDED </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Plaintiff hereby demands a trial by jury. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: March&nbsp;24, 2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Respectfully submitted,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>HALPER SADEH LLP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By: <U>/s/ Daniel Sadeh&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Daniel Sadeh, Esq.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Zachary Halper, Esq. (to be admitted <I>pro hac </I><I>vice</I>)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">667 Madison Avenue, 5th Floor</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York, NY 10065</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Telephone: (212) <FONT STYLE="white-space:nowrap">763-0060</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Facsimile: (646) <FONT STYLE="white-space:nowrap">776-2600</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Email: sadeh@halpersadeh.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; font-size:10pt; font-family:Times New Roman">zhalper@halpersadeh.com</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><I>Counsel for Plaintiff</I></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>tlry-20210315.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: 67.5 -->
<!-- Creation date: 3/26/2021 2:14:59 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:tlry="http://www.tilray.com/20210315"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:us-types="http://fasb.org/us-types/2020-01-31"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.tilray.com/20210315"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tlry-20210315_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tlry-20210315_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.tilray.com//20210315/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>tlry-20210315_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: 67.5 -->
<!-- Creation date: 3/26/2021 2:14:59 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Country</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Country</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>tlry-20210315_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: 67.5 -->
<!-- Creation date: 3/26/2021 2:14:59 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.tilray.com//20210315/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="tlry-20210315.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.tilray.com//20210315/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="20.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="21.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="26.031" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="26.131" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry" order="26.231" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="26.331" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="31.011" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>d117514d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tlry-20210315.xsd" xlink:type="simple"/>
    <context id="duration_2021-03-15_to_2021-03-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001731348</identifier>
        </entity>
        <period>
            <startDate>2021-03-15</startDate>
            <endDate>2021-03-15</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="duration_2021-03-15_to_2021-03-15"
      id="Hidden_dei_AmendmentFlag_duration_2021-03-15_to_2021-03-15">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2021-03-15_to_2021-03-15"
      id="Hidden_dei_EntityCentralIndexKey_duration_2021-03-15_to_2021-03-15">0001731348</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2021-03-15_to_2021-03-15">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2021-03-15_to_2021-03-15">2021-03-15</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2021-03-15_to_2021-03-15">Tilray, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2021-03-15_to_2021-03-15">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2021-03-15_to_2021-03-15">001-38594</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2021-03-15_to_2021-03-15">82-4310622</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2021-03-15_to_2021-03-15">1100 Maughan Rd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2021-03-15_to_2021-03-15">Nanaimo</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2021-03-15_to_2021-03-15">BC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry contextRef="duration_2021-03-15_to_2021-03-15">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="duration_2021-03-15_to_2021-03-15">V9X 1J2</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2021-03-15_to_2021-03-15">844</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2021-03-15_to_2021-03-15">845-7291</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2021-03-15_to_2021-03-15">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2021-03-15_to_2021-03-15">true</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2021-03-15_to_2021-03-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2021-03-15_to_2021-03-15">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2021-03-15_to_2021-03-15">Class&#160;2&#160;Common&#160;Stock,&#160;$0.0001&#160;par&#160;value&#160;per&#160;share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-03-15_to_2021-03-15">TLRY</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-03-15_to_2021-03-15">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2021-03-15_to_2021-03-15">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140371412483944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 15, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 15,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Tilray, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-4310622<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1100 Maughan Rd<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nanaimo<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">BC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">V9X 1J2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">845-7291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class&#160;2&#160;Common&#160;Stock,&#160;$0.0001&#160;par&#160;value&#160;per&#160;share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TLRY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001731348<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M7.Z1*RX3C:'MF3=]$UJY%B9&OT@5UD:P0?-ZC*%5MDW9VZ)6K,Y:(%QI/,*
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M;%!+ 0(4 Q0    ( *"*>E)Z0Z_J[P   "L"   1              "  :\
M  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( *"*>E*97)PC$ 8  )PG
M   3              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#
M%     @ H(IZ4GC5FD=6!    !$  !@              ("!#@@  'AL+W=O
M<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( *"*>E*?H!OPL0(  .(,
M   -              "  9H,  !X;"]S='EL97,N>&UL4$L! A0#%     @
MH(IZ4I>*NQS     $P(   L              ( !=@\  %]R96QS+RYR96QS
M4$L! A0#%     @ H(IZ4APX9>H_ 0  / (   \              ( !7Q
M 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( *"*>E(D'INBK0   /@!   :
M              "  <L1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+
M 0(4 Q0    ( *"*>E)ED'F2&0$  ,\#   3              "  ; 2  !;
H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /H3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d117514d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.tilray.com//20210315/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d117514d8k.htm">d117514d8k.htm</File>
    <File>d117514dex991.htm</File>
    <File>d117514dex992.htm</File>
    <File>d117514dex993.htm</File>
    <File>tlry-20210315.xsd</File>
    <File>tlry-20210315_lab.xml</File>
    <File>tlry-20210315_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d117514d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d117514d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "tlry-20210315_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tlry-20210315_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "tlry-20210315.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "tlry",
   "nsuri": "http://www.tilray.com/20210315",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d117514d8k.htm",
      "contextRef": "duration_2021-03-15_to_2021-03-15",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.tilray.com//20210315/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d117514d8k.htm",
      "contextRef": "duration_2021-03-15_to_2021-03-15",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tilray.com//20210315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tilray.com//20210315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tilray.com//20210315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tilray.com//20210315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tilray.com//20210315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tilray.com//20210315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tilray.com//20210315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tilray.com//20210315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tilray.com//20210315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tilray.com//20210315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tilray.com//20210315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tilray.com//20210315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tilray.com//20210315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tilray.com//20210315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tilray.com//20210315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tilray.com//20210315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tilray.com//20210315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tilray.com//20210315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tilray.com//20210315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tilray.com//20210315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tilray.com//20210315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tilray.com//20210315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.tilray.com//20210315/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-21-096768-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-096768-xbrl.zip
M4$L#!!0    ( *"*>E(F0CDZ1R$  +6S   .    9#$Q-S4Q-&0X:RYH=&WM
M/6MSVS:VW^_,_0\8=[OKS.AM.['EQ+N.[62]39R,[>YV[Y<.1$(2&HI4"=*V
M^NOO.0</@A3U</Q*6W>FL222P,%YOP"^_OO-)&)7(E4RB=]L=%N=#2;B( EE
M/'JSD6?#YNX&^_O!__[/ZW$&-\+-L>K'21SGDS<;XRR;]MOMZ^OKULT@C5I)
M.FJ'6=K.9E/1AIN:<)=(9;!AGKN)9/RE]-CU%CW4W=O;:]-5>^O<G6Z"7J>S
MU<;+ ZZ$O3V+TEGI]DQ&*9^U@F0"#_2ZG:WNCH-"R3H88-QN^Z>/'RZ"L9CP
MIHQ5QN/ S9!GZ4)X]MIPU=XH5;+=Z[Y: KRYPSUPL^C>+MP;PU+%3V_//Q2W
M9_7W%[>VLY3':IBD$YX!67&DG6:GU^R]] 9I*A&4!H+OK5%RM7*<W>96U^$2
M)I?+EEK!(EX-BP?\FU^V]45[:R@J]UGXX +2M-/L=#U(<M5$ME/NF2%7 QK;
M7JEY2*79HJ?@TOP#BWD7I6.#Q$3P$/]F,HO$P6[SA]=M_1%^FXB,,QRA*7[-
MY=6;C:,DSD2<-2\!A@T6Z&]O-C)QD[5I1-;&Y]IF4,;8ZT$2SO#CZU!>,97-
M(O%F(Y1J&O$9RJ78.&"OY4T?GQ"I^2S#4,3Z,]QRIH62R?#-QC_ITL^ TI\/
M)R(.X?_L7<1'/X=Y2C3_&:6GV=EJ=G=^SA+OVP:+^03G%K)?>M2LXR8[%T.X
MO'*<@R&/E'C=+@&W"MB3&) Z.X(I4QZ=QJ&X^4',;@=T[1"W!KX#6N/55G=K
M>W=^!>T*[E,Q%"DH5Z'@.VJPOB)= W,Q4GY]Y,4W&TI.IA&*#/TV3A$45'!-
MJ\E:-RJTEWD:I DRP=JZ\@&T\,'K=GD]9O6E%=-WE>2I_DJJHV_03?1= ]WV
M,4'$<U]EB#\,I4@9@2!J%=O1Z0]E@E4?1JAKQY\"19/0?06=EF;'/!,'!6SV
MR>): 6NXX%Y[Q4WKYFF7L..P66"O[<MX&W3!04DCX%--'LE1W ]@+2+=*%^_
MEF$V[N^V=F2\[]T;B6&V/^'I2,9-_-QG/,\2^TLJ1V/S$PXWM8.AN6B.!5T%
M!V+JALB2:=_[.DBR+)G0+X,D!=#M+]WI#5-))$/V78?^VSCXZW?=EYW]U^WI
MHHFV5D_4^^J)O&&W81 VOP V!-(TE?Q-]+N[[ON03V0TZU_*B5#L3%RS\V3"
MXWVZ=JWA'B11N%]#GA_/3B]/CMG%Y>'ER<5B<#J/!,[%R=&/YZ>7IR<7[/#L
MF)W\=/3/P[/W)^SHT\>/IQ<7IY_.[@1C[SY@_,_AQ3]/S]Y??CIKL./648OU
M.CO;>Q6XO$G7X<PR0ZR2J%K.?/E5G-GJP&UEYMS74MKK?C^_^C6EM%B,51)U
M!.L^%E>]^W3^D;U64QX[1326F6C"+X$ XWF=\BD8D[+I+TSV<1+DZ&9X[M+Z
MEII<L;*)?MU&4 Z>.>9!..9>9!RTT/G)V24[/_G\Z?SRZ77.YSQ5.8\SEB7L
M0@3(<QICW2V6I*R[LQF^>'HHDR'+Q@(!S%.927C^Y"88\W@DV&&0,;C<W=O:
M7@SGHY$7W1\$YUQ,DS1CF_:[X.#^")4Q<05WLI0NB_!%OQH7S"N'S^1#G6C7
MZK9:@NE@]\T&!,C]$ :8P./CD,]F )&(-PX^@K\]-A3?:3!\=%ZK/*N3^U<G
MO>W[X+<*]]R2.:K!X[D8284YDNP,KFP<7%+2J<%.XZ"U@BMNIQ0Z]['VS9,;
M#L*/B] B9X%G7+&+J0@P!@J9C-EIIMC1&.(8D5:5V3,W+^#FNR &TT5\$ D6
MB"A"7XB2KYT-^C[E86B_F[G,6H,DBOA4B;[]L)Q'/(9"9TYCH]OI?&]PU^\8
M,/L=&^,A8*G^$Y9#QZWM[S'JSW2NRUV\$FDF QX9Y.KUUMUH1NFM/XH%N/:)
MZG#PCX$[M;=,^4@T!ZG@7S"W"T%_GU\EP!UK(ZU+9"M-RSQ&8B5.ZA,/L<I*
M@!T 0-__K0KN?:LH4$5)"L:3GKO(P*(=)7F<I;.C)!0E<X?Y8,Q>9&*:)E<X
M#MJ[8Q'Q:S!]"UWG-3G <GOU]@?!X"T#C#NB^)V,! PU0!W6P6SQ[L[>]D)\
M/:/-H.V2WYR:S%M SUH<[O::VUO=SLM>;PTD/H2@[]Z3G'^=L;^70'N31!TC
MDD\0"*3L7Q 'J%!2O$+F:TW8N@\ &_@>):WT0MO3)Y&(IR3143*92*6^ 8J@
M!F-:_/ZLQ#@]OV GDVF4S$3ZU.0HJT5VEK0*JFA]!_^BO_B[]3\)Q+LYH#N=
M>W4=MW>_<=?1N=)/&4+>KP=P&(:I4,K\^0 Q7W?CH L,P3[R?#0&9^0\K+H
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M=UR(!%##VK2; <A?O3*,C%%<T%.PF 8BK L6OOM!]=MMF?KO 9)FGF9JYS$
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MT.70]6_EN?XBX,IVQ10A >&G^JL:)WD45G\-ZGX4,2KIZJ_3!%_=+9%'JV.
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MCJY- P:QI[0@A0LW3;C#1SK@5W.FIW:Y$P[AA_Q-+Q>"LDC^YN=!2*.9/;G
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M>U6*]OCHY%B*E(N%U5!91"B7S5D^8+E@Q@@CT(+55*I3JU53^[GIU[0"B)W
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M-S4Q-&1E>#DY,BYH=&WM?6ES&DFZ[G<B^ \9GM,GI B$!=IEM^(BA&QZM%U
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M:E.U'R,%Q3)*@ -XJ(;4\=USZ8:V'B' 8 2*51'!$*X"R1Q-A9LF4]C,<FD
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MWOE($BV0;-?H O9_ED@+ZT1HU] US!HP>.SU?1#5J7EB$@$H5Z,-0B/0APZ
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M DD)& EB#)ZP<8-6Y\SS*H\'?!P7)K&1QE+'?+)[29RH3QL *0%-N6!.@Y!
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M0.-_4H7B<20)#ZAQV+ ^N\KB$$2^AF413[,+7XO20>0,$RP3!H3.\@B$C9<
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M0 *\@/W=>F+-Z;*):M6SL#9U+:L&-+65 !BP,'"=7V'EPQ#/SJ]?K8A (HC
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M%X=I-)!QMJ'J(57,7K#W<V?UC')@SN<CR4)HC%; A,P6>K]I]I1@6G"S_.)
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M1_C5LB,7?L(1[FSMW&6$NSMK&SOK+S;"SL1RO7T1X>GXK['E365(?]?M8+*
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M22X=/V:0H@N=-/(0630H*-:E)\6)4E9P2Y8:_YH.Z$%K%Y'4IK]T<PX3T(>
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MAX 00UP\N!DMS:E+(.^,6M'E?)1+V(IC3\)<&=^", I"V/^@)@ '3V!DL6+
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M(NXDM52PQR!B^E!RA?#. @/>T]KJ:@HZ8O%C>\8,=C=%-Z?AJDF2*T'-K;:
MSLG8KMJVP''$TQIS0?*[V(QHRRP3_,$L?["JB_+:(V=B]C:5B0%C=!([+NN*
M46R*PG&AF67OEBQ[2V+WGM&X=]YK?N_TQ->SGNAUCKN=KV_'-@4#_/.HT^O
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MQWQ#JDO^ 5!+ 0(4 Q0    ( *"*>E(F0CDZ1R$  +6S   .
M  "  0    !D,3$W-3$T9#AK+FAT;5!+ 0(4 Q0    ( *"*>E*[<SMK^"(
M "JS   1              "  7,A  !D,3$W-3$T9&5X.3DQ+FAT;5!+ 0(4
M Q0    ( *"*>E)Z;ABG<3,  $?[   1              "  9I$  !D,3$W
M-3$T9&5X.3DR+FAT;5!+ 0(4 Q0    ( *"*>E+3TVNY;C4  #T= 0 1
M          "  3IX  !D,3$W-3$T9&5X.3DS+FAT;5!+ 0(4 Q0    ( *"*
M>E*"8Q-R'0,  ,0*   1              "  =>M  !T;')Y+3(P,C$P,S$U
M+GAS9%!+ 0(4 Q0    ( *"*>E(^^92PD 8  /Y&   5              "
M 2.Q  !T;')Y+3(P,C$P,S$U7VQA8BYX;6Q02P$"% ,4    " "@BGI2),KD
MB+@$  "A+   %0              @ 'FMP  =&QR>2TR,#(Q,#,Q-5]P<F4N
9>&UL4$L%!@     '  < O@$  -&\      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
